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PCR polymerase chain reaction
r correlation coefficient
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rpm rounds per minute
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jj.1 microliter(s)
jig microgram(s)
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INTRODUCTION
Insulin-dependent diabetes mellitus (©DM ) is one of the most severe and 
common metabolic diseases of childhood. It has major impact on the society as 
for cost. IDDM occurs most frequently in persons of Northern European de­
scent. The incidence of IDDM among children ranges from 1.7 per 100,000 per 
year in Japan to 35 per 100,000 per year in Finland (Karvonen et al., 1993). In 
Estonia the incidence of IDDM is about 10 per 100,000 per year (VII, VIII).
IDDM is a chronic disease with yet unknown aetiology. Therefore, no effec­
tive measures for the prevention of the disease are available. Evidence accumu­
lated over the last two decades has strongly supported the hypothesis that 
IDDM develops in genetically susceptible individuals by an autoimmune 
mechanism.
To support this hypothesis, antibodies to pancreatic islet cells have been 
found (Bottazzo et al., 1974; Atkinson and Maclaren, 1993). Not just humoral 
immune abnormalities, but also cell-mediated ones have been found in the 
peripheral blood of patients (Drell and Notkins, 1987; Atkinson et al., 1992; 
Harrison et al., 1993; Rabinovitch, 1994). The Langerhans islets of persons 
with IDDM have been infiltrated with mononuclear cells, and histologically 
insulitis and beta-cell destruction documented (Bottazzo et al., 1974, 1986; 
Tisch et al., 1993; Atkinson and Maclaren, 1994). IDDM is often concurrent 
with other autoimmune abnormalities such as autoimmune thyroid disease, 
pernicious anaemia, Addison’s disease, idiopathic hypoparathyroidism, primary 
hypogonadism, myasthenia gravis, vitiligo, alopecia totalis, coeliac disease 
(Bottazzo et al., 1974, 1986; Drell and Notkins, 1987; Wagner et al., 1994; 
Björk et al., 1994).
IDDM is strongly associated with certain HLA-linked immune response 
genes (Raum et al., 1979; Vardi et al., 1987; Deschamps et al., 1991; Tuomi­
lehto-Wolf et al., 1991; Todd, 1995; Routsias and Papadopuolus, 1995). Genes 
in the HLA region on chromosome six confer the major genetic susceptibility to 
IDDM (Todd et al., 1987; Tuomilehto-Wolf and Tuomilehto, 1991). The role 
of HLA in IDDM was first indicated by association with HLA-B8 and В 15 
(Singal and Blajchman, 1973). Subsequently a stronger association was found 
with HLA-DR3 and HLA-DR4 antigens encoded at the HLA-DRB1 locus 
(Thomsen et al., 1975; Svejgaard et al., 1980; Overbach et al., 1983; Wolf et 
al., 1983). More recently, HLA-DQB 1 and HLA-DQA1 genes were shown to 
be even more strongly associated with IDDM (Todd et al., 1987; R0nningen et 
al., 1991; Thorsby and R0nningen, 1993). The proteins encoded by HLA class 
П genes are antigen-presenting molecules and may confer protection or suscep­
tibility for the development of IDDM (Thorsby and R0nningen, 1993).
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According to widely accepted concept of the etiopathogenesis of DDDM, 
environmental factors such as microbial agents and chemicals act as triggers of 
an autoimmune response against pancreatic islet beta-cells in genetically IDDM 
susceptible individuals (Yoon, 1990; Vreugdenhil et al., 1998; Saukkonen et 
al., 1998). Certain viruses have been associated with the induction of IDDM in 
humans, notably rubella, mumps, Coxsackie and cytomegalovirus (Rubinstein 
et al., 1982; Helmke et al., 1986; Guberski et al., 1991; Gaskins et al., 1992). 
Molecular mimicry between epitopes common to microbial antigens and host 
proteins has often been implicated in induction of autoimmune disease in man 
(Hyôty et al., 1995; Vreugdenhil et al., 1998).
However, there is still confusion concerning the interpretation of the com­
plex, often discrepant, immune and genetic associations with IDDM. For that 
reason, studies of different populations of varying genetic and environmental 
backgrounds are needed for better understanding of the aetiology and patho­
genesis of IDDM. Until now, insufficient information is available on the preva­
lence of IDDM associated immune and genetic factors in Estonia.
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BACKGROUND OF THE STUDY
1. Immune factors of IDDM
The humoral autoimmunity is extensively studied in IDDM. The most com­
monly reported immunological abnormalities in IDDM are autoantibodies 
reacting with pancreatic islet-cell antigens. Many autoantibodies have been 
described in IDDM. It has become harder to identify those antibodies that are 
the most important and involved in the primary immunological events of the 
autoimmune disease process. The following is an incomplete list of the autoan­
tigens against which antibodies have been detected in IDDM — insulin, sialo- 
ganglioside of islet cells, glutamic acid decarboxylase, insulin receptor, islet ty­
rosine phosphatase, glucose transporter, carboxypeptidase H, cow milk protein 
(Bottazzo et al., 1974; Baekkeskov et al., 1982; Borch-Johnsen et al., 1984; 
Atkinson and Maclaren, 1993, 1994; Christie et al., 1990; Christie, 1993; 
Martin et al., 1991; Saukkonen et al., 1998).
1.1. Islet cell antibodies
Islet cell antibodies (ICA) were first described in IDDM patients who had other 
coexistent autoimmune endocrine disorders by Bottazzo and colleagues in 
1970s (Bottazzo et al., 1974). The initial description of ICA provided strong 
evidence for an autoimmune etiology and pathogenesis of IDDM.
ICA react with antigens in the cytoplasm of all endocrine cells of pancreatic 
islets and are shown by conventional indirect immunofluorescence (IFL). They 
are exclusively of immunoglobulin G (IgG) class (Atkinson and Maclaren,
1994). The target antigen recognized by ICA in IFL assays has been suggested 
to be a sialoganglioside (Nayak et al., 1985). Some ICA, in particular those of 
high titre, can fix complement. This has been shown predominantly in newly 
diagnosed IDDM patients and in individuals genetically predisposed to IDDM 
(Karjalainen et al., 1986; Bonifacio et al., 1989).
Natural history of IDDM has been defined through studies of nondiabetic 
subjects who had IDDM-associated autoantibodies years before the onset of 
hyperglycemia. Measurement of ICA in prospective studies of individuals at 
high risk to develop © D M  has established that the abnormal immunological 
state against beta-cells precedes the clinical onset of the disease by up to sev­
eral years (Kobayashi et al., 1987; Kuglin et al., 1989; Bruining et al., 1989; 
Bingley et al., 1993). The standardization of ICA measurements and the intro­
duction of reference Juvenile Diabetes Foundation units (JDFU) have enabled 
better comparison of data from different centers (Lemmark et al., 1991).
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ICA are found shortly after diagnosis in most of IDDM patients (Table 1). 
The percentage of ICA positive individuals ranges from 67 to 93 in different 
studies.
Table 1. Prevalence (%) of ICA in newly diagnosed IDDM patients (IDDM) and 
healthy first degree relatives of IDDM patients (Relatives)
IDDM
Kolb et al. (1980) 83
Lernmark et al. ( 1981) 67
Notsu et al. (1985) 63
Karjalainen et al. (1986) 75
Landin-Olsson et al. (1989) 81
Genovese et al. (1992) 89
Bonifacio et al. (1995) 93
Gorus et al. (1997) 73
Wiest et al. (1997) 75
Savola et al. (1997) 84
Relatives
Gorsuch et al. (1980) 4.0
Thivolet et al. (1988) 5.1
Bonifacio et al. (1989) 3.3
Kuglin et al. (1989) 3.5
Seissler et al. (1996) 6.9
Gorus et al. (1997) 5.0
In IDDM patients, ICA tend to disappear from the circulation a few weeks or 
months after diagnosis (Kolb et al., 1980; Atkinson and Maclaren, 1993). Sev­
eral reports have shown that some IDDM patients continue to be ICA positive 
with lower titers for a long period after diagnosis (Kobayashi et al., 1987,
1993). The prevalence of ICA gradually decreases with time and eventually 
drops to 12-35% in IDDM patients with duration of five years or more 
(Kobayashi et al., 1987, 1993; Kolb et al., 1988). Considering the 10-30% of 
the IDDM patients negative for ICA at diagnosis, these might have been 
recruited from subjects with previous transient ICA positivity and disappear­
ance of ICA from sera would occur when pancreatic beta-cells have been com­
pletely destroyed. ICA may reflect ongoing autoimmune beta-cell destruction 
and the ICA titer the extent of this beta-cell destruction. Patients with ICA 
positivity are considered to have some residual beta-cell function (Kolb et al., 
1988; Kobayashi et al., 1993).
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Table 2. Prevalence (%) of ICA in background population and annual incidence of 
childhood onset IDDM (per 100,000) in selected populations participating in Interna­
tional ICA Standardization Workshop. Data from Bergay et al., 1983; Bingley and Gale, 
1989; Landin-Olsson et a i, 1989; Nyström et al., 1990; Karjalainen, 1990; Tuomilehto 
et al., 1991; Green et al., 1992; Muntoni et al., 1992; Levy-Marchal et al., 1992; 
Bingley et al., 1993; Schatz et al., 1994.
Population Individuals
studied
Age range 
(years)
Prevalence of 
ICA
Incidence of 
IDDM
Finland 1212 3-18 4.1 35
Sardinia 1894 6-17 3.2 30
Sweden 321 0-14 3.0 24
UK 242 5-17 2.2 13
France 8363 6-17 1.8 8
USA 9696 5-17 0.6 16
Spain 2291 3-15 0.4 12
ICA have been found also in nondiabetic first degree relatives of patients with 
IDDM. The prevalence of ICA in relatives of IDDM patients has been reported 
to be lower than in newly diagnosed patients (Table 1). It ranges usually from 
three to seven percent. It has been suggested that the progression to IDDM in 
relatives depends on the titer of ICA (Bonifacio et al., 1989; Karjalainen, 
1990). Bottazzo and colleagues have found that all first degree relatives with 
ICA>80 JDFTJ developed IDDM within seven years of follow up. In those with 
ICA between 20 and 80 JDFU, the probability of being free of IDDM after ten 
years was only 27% (Bottazzo et al., 1991). In other studies, IDDM was more 
likely to appear in relatives with high titre of ICA if they were young or from 
multiplex IDDM families (Riley et al., 1990).
ICA are present in the serum of approximately 0 .5 ^  percent of healthy 
subjects (Table 2). Finland has reported the highest prevalence of ICA and the 
highest incidence of IDDM in the world (Karjalainen, 1990). There seems to be a 
close correlation between the incidence of the disease and the prevalence of ICA 
in nondiabetic children in various countries (Bergay et al., 1983; Landin-Olsson 
etal., 1989; Karjalainen, 1990; Levy-Marchal et al., 1992; Muntoni et al., 1992; 
Bingley et al., 1993; Schatz et al., 1994). The prevalence of ICA exceeds the 
prevalence of IDDM many times and ICA might, therefore, occur transiently 
without subsequent development of diabetes (Landin-Olsson et al., 1989).
1.2. Glutamic acid decarboxylase antibodies
Autoantibodies to a 64 kD islet protein were first reported in 1982 by Baekke- 
skov and coworkers (Baekkeskov et al., 1982). Later the 64 kD protein was 
identified as glutamic acid decarboxylase (GAD), the major antigen for autoan­
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tibodies from IDDM patients (Baekkeskov et al., 1990). GAD catalyzes the 
formation of gamma amino butyric acid, a neuroinhibitor in the central nervous 
system. GAD is also expressed in the islets of Langerhans and other tissues. 
Some factors suggest that GAD may play a role in the pathogenesis of ©DM . 
Mononuclear cells from IDDM patients have been shown to proliferate in 
response to GAD (Tisch et al., 1993). The immunocytochemical ICA is likely a 
composite of antibodies directed at several pancreatic islet molecules, one of 
the target antigens being GAD (Martino et al., 1991; Genovese et al., 1992; 
Atkinson and Maclaren, 1993). A number of assays for GADA have been de­
veloped, including immunoprécipitation methods. The quantitative radiobind­
ing assay has higher sensitivity than other methods and is more simple and 
reproducible (Hagopian et al., 1993; Schmidli et al., 1995).
GADA are found by radiobinding assay in 65-87% of individuals with 
newly diagnosed IDDM (Baekkeskov et al., 1990; Karlsen et al., 1992; 
Schmidli et al., 1994; Bonifacio et al., 1995) (Table 3). GADA precede the 
diagnosis of IDDM by several years (Genovese et al., 1992; Thivolet et al., 
1992; Aanstoot et al., 1994; Tuomilehto et al., 1994; Yu et al., 1996). GADA 
levels are reported to be influenced by age, sex and ICA status, and generally 
remain stable after the onset of clinical IDDM (Martino et al., 1991; Bingley et 
al., 1994; Schmidli et al., 1994; Jaeger et al., 1997). GADA have been found 
several years after diagnosis, in the majority of patients for up to 10-20 years 
after the diagnosis of IDDM with some decrease in antibody frequency 
(Rowley et al., 1992; Tuomi et al., 1993).
Table 3. Prevalence (%) of GADA in newly diagnosed IDDM patients (IDDM), healthy 
first degree relatives of IDDM patients (Relatives) and background population 
(Controls)
Study IDDM Relatives Controls
Karlsen et al. (1992) 75 1.7
Petersen et al. ( 1994) 74 2.5
Bonifacio et al. (1995) 65 1.0
Seissler et al. (1996) 87 6.3 1.0
Kulmala et al. (1995) 9.6
Gorus et al. (1997) 82 6.0
Wiest et al. (1997) 75 6.4
Savola et al. (1997) 73
Zanone et al. (1997) 53
Jaeger et al. (1997) 78
Ortego et al. (1997) 5.6
Vähäsalo et al. (1997) 6.5
Velluzzi et al. (1997) 2.1
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Among the healthy first degree relatives the prevalence of GADA has been 6.0— 
9.6% (Chen et al., 1993; Roll et al., 1994; Seissler et al., 1996; Gorus et al., 
1997). The highest prevalence has been reported from Finland (Kulmala et al.,
1995). Population screenings for GADA have shown the frequency in healthy 
control subjects up to 2.5%, exceeding the prevalence of IDDM five to ten 
times (Petersen et al., 1994; Leech et al., 1995; Aanstoot, 1995).
1.3. Tyrosine phosphatase antibodies
Christie and coworkers described a novel antigen in the beginning of 1990s as 
an islet protein with molecular weight of 37 kD/40 kD (Christie et al., 1990, 
1992a, 1992b). Recently Christie and co-workers identified the 40 kD antigen 
as the intracytoplasmic domain of the tyrosine phosphatase IA-2 (Christie et al.,
1993). Several groups provided evidence that LA-2 is the precursor of the islet 
37 kD and 40 kD polypeptide autoantigens and as one of the ICA specificities 
(Payton et al., 1995; Rabin et al., 1994; Passini et al., 1995; Zimmet, 1996; 
Solimena et al., 1996). Detection of antibodies to IA-2 by a radio-binding assay 
allows quantitative measurements of these autoantibodies (Grubin et al., 1994; 
Wiest-Ladenburger et al., 1997). It has been suggested that antibodies to tyro­
sine phosphatase (IA-2A) may be a sign of rapid progression to IDDM (Christie 
et al., 1994; Leslie et al., 1995).
Table 4. Prevalence (%) of tyrosine phosphatase antibodies (IA-2A) in newly diagnosed 
IDDM patients (IDDM), healthy first degree relatives of IDDM patients (Relatives) and 
background population (Controls)
Study IDDM Relatives Controls
Gianani et al. (1995) 38
Bonifacio et al. (1995) 62 0
Seissler et al. (1996) 4.4 0
Genovese et al. (1996) 61
Gorus et al. (1997) 58 1.5 0.8
Kawasaki et al. (1997) 41 1
Wiest et al. (1997) 73 2.9 0
Savola et al. (1997) 73
Zanone et al. (1997) 64
Velluzzi et al. (1997) 2
De Leeuw et al. (1997) 49
Kulmala et al. (1997) 5.1
Few studies have investigated the prevalence of IA-2A (Table 4). LA-2A have 
been found in 38-73% of IDDM patients at the time of diagnosis. The highest 
frequency of these antibodies (73%) has been reported from Germany and 
Finland — 73% (Wiest-Ladenburger et al., 1997; Savola et al., 1997). Lower
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values have been documented in Japan and Italy (Kawasaki et al., 1997; 
Gianani et al., 1995).
IA-2A have been found in 1.5-4.4% of healthy relatives of IDDM patients. 
Gorus and coworkers have detected LA-2A only in 1.5% of relatives (1997). 
Seissler’s group found LA-2A in 44%  of first degree relatives, which is com­
parable to the frequencies of ICA and GADA (1996). The few studies investi­
gating the frequency of LA-2A in background population have documented 
these antibodies in 0-2% of individuals. The highest prevalence was reported 
by Velluzzi and colleagues, in 2%, also similar to prevalence data of ICA and 
GADA in the background population (1997).
2. Genetic factors of IDDM
Although a variety of genetic markers have been studied in relation with 
IDDM, most of the research has concentrated at the HLA system. The associa­
tion of HLA antigens with IDDM was discovered more than 20 years ago. 
Singal and Blajchman found an increase of class I molecules B8 and В 15 in 
IDDM patients compared with controls (1983). Since then many reports from 
different countries have confirmed and extended these findings (Raum et al., 
1979; Tuomilehto-Wolf and Tuomilehto, 1991; Fennesy et al., 1994; Gemaine 
et al., 1995). Family studies confirmed genetic linkage between HLA and 
IDDM, suggesting that genes within or near the HLA region are involved in the 
susceptibility for the disease (Overbach et al., 1983; Thomson et al., 1988; 
Deschamps et al., 1991; Reijonen et al., 1994; Honeyman et al., 1995). Recent 
genome-wide mapping studies have confirmed that the HLA class П region 
encodes the most important determinants of protection against and susceptibil­
ity to IDDM (Tiwari and Terasaki, 1985; Todd et al., 1987, 1989; Nepom, 
1990; R0nningen et al., 1991; Harrison and Tait, 1991; Deschamps et al., 1993; 
Davies et al., 1994; Routsias and Papadopuolus, 1995; She, 1996). However, 
data from different populations show that there is still confusion concerning the 
interpretation of the complex HLA associations with IDDM (She, 1996).
2.1. HLA-DRB1 alleles
Certain serologically determined HLA-DR locus antigens were shown to be 
associated with IDDM after the initial revelation of the link between the disease 
and HLA-B locus (Svejgaard et al., 1980; Wolf et al., 1983; Marshall et al.,
1994). After the discovery that some HLA-DQ locus alleles were more strongly 
related to IDDM, the importance of the contribution of the HLA-DR locus was 
temporarily underestimated. Recent studies have reconfirmed the importance of
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the HLA-DR alleles in the determination of the risk of IDDM (Olerup et al 
1992; Undlien et al., 1995; Van der Auwera et al., 1995; Honeyman et al., 
1995; Sanjeevi et al., 1996). HLA-DR alleles can convey susceptibility or 
protection against IDDM (Van der Auwera et al., 1995; Tait et al., 1995) 
(Table 5).
Table 5. HLA-DRB1 alleles proposed to confer susceptibility to or protection against 
IDDM.
Susceptibility
*0301
*0401
*0402
*0405
Protection
*02
*0403
*0406
*0408
*11
*13
*14
*15
The HLA-DR antigens most often associated with the increased risk of the 
development of IDDM, are DR3 and DR4 (Deschamps et al., 1984; MacMillan 
and Foster, 1991; Kockum et al., 1995). In Caucasians, more than 90% of 
IDDM patients are HLA-DR3 or HLA-DR4 positive, compared with 40-50% 
of controls (Caillat-Zucman et al., 1992). The same group has found that the 
greatest risk is in HLA-DR3/DR4 heterozygous individuals, who make up 30- 
50% of IDDM patients (1992). Frequencies of DR3 and DR4 were also signifi­
cantly increased in both the © D M  cases and their unaffected siblings com­
pared with the general Southeast US population (MacMillan and Foster, 1991). 
MacMillan’s investigation showed that 46% of IDDM children possessed both 
DR3 and DR4 antigens while only 7% had neither (1991). Among Brazilian 
IDDM patients DR3 was detected in 57% of the patients versus 28% of the 
controls and DR4 in 54% of the patients versus 23% of the controls (Eizirik et 
al., 1987). Eighty seven percent of IDDM patients had HLA-DR3 and/or DR4 
versus 36% of the Venezuelan general population (Gunczler et al., 1993). Hon­
eyman and coworkers have shown that HLA-DR4 conveys a greater risk of 
IDDM than HLA-DR3 in familial cases (1995). In a Sardinian study the geno­
type analysis of the patients showed a strong increase of the DR3/DR4 het­
erozygotes with a relative risk higher than that of the DR3 and DR4 homozy­
gotes (La Nasa et al., 1990). Among Moroccan IDDM patients HLA-DR3 had a
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strong positive association with the disease (68% of patients versus 33.3% of 
controls) (Izaabel et al., 1996). The DR7 association with IDDM is specific for 
the Negroid race, and DR9 is only weakly associated in Caucasoid and Negroid 
subjects (Fletcher et al., 1988). In the study from Korea the frequencies of 
HLA-DR3, DR4 and DR9 were also higher in IDDM patients compared with 
the control population (Lee et al., 1996).
HLA-DR2 appears as protective against IDDM from multiple studies 
(Eizirik et al., 1987; Thomson et al., 1987; Lee et al., 1996). Other HLA-DR 
antigens contributing to protection against IDDM are DR7 and DR 15 (Eizirik et 
al., 1987; Awata and Kanazawa, 1994; Kockum et al., 1995). The frequency of 
DR2 was significantly decreased in Korean IDDM patients in comparison with 
controls (Lee et al., 1996). Sanjeevi and coworkers found that DR2 was detect­
able in only 3% of IDDM patients and 28% of controls (1994). In Sardinia, the 
DR2 antigen was also negatively associated with IDDM in the central island 
districts (La Nasa et al., 1990). In Brazil, DR2 was seen in 11% of the patients 
versus 31% of the controls and DR7 in 3% of the patients versus 21% of the 
controls (Eizirik et al., 1987). Generally, HLA-DR2 appears to be inversely 
associated with IDDM in all races (Thomson et al., 1988).
Recent studies have analyzed the subtypes of HLA-DR4 with molecular 
techniques. Interestingly, only some HLA-DR4 subtypes evidently convey sus­
ceptibility to IDDM, while others may even provide protection against the 
disease. Data is contradictory. The strongest susceptibility in some ethnic 
groups is related to HLA-DRB 1*0405, followed by *0402, *0401 and *0404. 
HLA-DRB 1*0403, *0406 and *0408 provide protection (Harrison and Tait, 
1991; Caillat-Zucman et al., 1992; Van der Auwera et al., 1995; Sanjeevi et al., 
1996; She, 1996). Undlien and coworkers have shown that some DR4 subtypes, 
such as DRB 1*0405, *0402, and *0401, confer little or no protection, while 
others, DRB 1*0404, *0403, and *0406 cause an increasing degree of protection 
(1995). The most common HLA-DR4 subtype in the Swedish © DM  patients 
was HLA-DRB 1*0401, found in 62%. DRB 1*0404 was decreased in the 
IDDM subjects compared with controls (4.8% versus 19.0%) (Sanjeevi et al., 
1996). DRB 1*0401 also conferred the highest risk of IDDM in Norway, fol­
lowed by *0404 and *0403 (Yasunaga et al., 1996).
2.2. HLA-DQB1 alleles
After the documentation of the association of IDDM with HLA-DR locus, sus­
ceptibility to or protection against IDDM was found to be even more strongly 
linked to some HLA-DQ alleles (Todd et al., 1987, 1989; Thorsby and R0nnin- 
gen, 1993; Tosi et al., 1994) (Table 6). Todd and coworkers proposed the 
primary role for residues on the HLA-DQB 1 gene in IDDM susceptibility 
(1987). While sequencing HLA-DQB 1 alleles of IDDM patients and controls,
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they noticed that non-aspartic acid residue in the 57th position (non-Asp-57) of 
the HLA-DQß chain was associated with higher risk of IDDM (Todd et al., 
1989). Studies in several populations have correlated the frequency of the 
HLA-DQB 1 non-Asp-57 alleles with differences in IDDM incidence (Awata et 
al., 1990; Deschamps et al., 1991; Cruickshanks et al., 1994; Chauffert et al., 
1995; Sanjeevi et al., 1995). Only 25.5% of the IDDM subjects were pheno- 
typed as having aspartic acid in the 57th position of the DQß chain compared 
with 82% of control subjects. This suggests that Asp-57 negativity is a definite 
risk marker for developing IDDM in Finnish patients (Reijonen et al., 1991). 
The specific HLA-DQB 1 alleles that do not code for aspartic acid in the 57th 
position of the DQß chain, are DQB 1*0201, *0302, *0501 and *0502 (Chauf­
fert et al., 1995). Caillat-Zucman with coauthors has found that among Cauca­
sians 74.6% of IDDM patients had DQB 1*0201 and 59.2% DQB 1*0302 allele 
compared with 33.2% and 11.8% in controls, respectively (1992). Harfouch and 
colleagues found DQB 1*0302 allele in most of IDDM patients (94.2%) com­
pared with lower prevalence (64.7%) in controls (1996). In Sardinia, where the 
incidence of IDDM is very high, the DQB1 molecular analysis showed only 
three alleles in IDDM patients: DQB1*0201 (75.8%), DQB1*0302 (16.1%), 
and DQB 1*0502 (8.1%). It seems that nearly if not all Sardinian ©DM pa­
tients are non-Asp-57 homozygotes. The DQB 1*0502 allele, extremely rare in 
other Caucasian populations, represents in Sardinia about 70 per cent of the 
HLA-DR2 haplotypes, contributing to the increase of the pool of IDDM suscep­
tible genes (La Nasa et al., 1990).
Table 6. HLA-DQB 1 alleles proposed to confer susceptibility to or protection against 
IDDM.
Susceptibility
*0201
*0302
*0501
Protection
*0301
*0401
*0402
*0601
*0602
*0603
Recent papers have informed that HLA-DQB 1 *0304 is a rare allele combining 
features of both HLA-DQB 1*0301 and HLA-DQB 1 *0302 alleles. Similarly to 
HLA-DQB 1*0302 the 57th amino acid of the ß chain of HLA-DQB 1 *0304 is a 
non-Asp amino acid (alanine) suggested crucial in susceptibility to IDDM 
(Cucca et al., 1994).
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Some DQB1 alleles appear protective against © DM . HLA-DQB 1 *0602 
provides the strongest protection. Pugliese and со workers have found that 
DQB 1*0602 is protective from © D M  both in population studies and among 
relatives compared with © D M  patients (1995). Caillat-Zucman and co-investi­
gators showed that DQB 1 *0602/0603 was present in 35% of unrelated Cauca­
sian controls compared with 3% of © D M  cases (1992). Among Moroccan 
© D M  cases the frequency of DQB 1*0602 was 2% compared with 14% in con­
trols (Izaabel et al., 1996). In Korea both DQB1*0301 and DQB1*0601 were 
negatively associated with © D M  (Lee et al., 1996). Also in Japan and Norway 
DQB 1*0301 was less frequent in © D M  patients (Yasunaga et al., 1996). 
Ilonen’s group has found that among healthy siblings of © DM  patients 
DQB 1*0301 was associated with weaker protective effect against © DM  com­
pared with those having DQB 1 *0602/0603 (Ilonen et al., 1996)
2.3. HLA-DQA1 alleles
In 1990 Khalil and coworkers performed extensive HLA-DQA1 and HLA-DQB 1 
typing in Caucasian © D M  patients and found that arginine in the 52nd position 
of the HLA-DQa chain, corresponding to HLA-DQA 1*0301 and *0501 alleles, 
was associated with higher risk for © DM . During the years to follow, many 
authors have confirmed that arginine in the 52nd position of the HLA-DQa 
chain correlates highly significantly with © D M  (a  chain, corresponding to 
HLA-DQA 1*0301 and *0501 alleles, was associated with higher risk for 
©DM . During the years to follow, many authors have confirmed that arginine 
in the 52nd position of the HLA-DQa chain correlates highly significantly with 
© D M  (s, respectively (1992). A study from Colorado found DQA1*0301 in 
70-80% and DQA1*0501 in 58-61% of © D M  cases and about twice less fre­
quently in control group (Cruickshanks et al., 1994). Analysis of the frequency 
of the subtypes of DQA1 alleles among Japanese © DM  patients showed that 
the DQA 1*0301 allele was the most strongly associated with the disease 
(prevalence of 97.4% in © D M  cases versus 56.7% in controls) (Tanaka et al.,
1992). Izaabel and colleagues have shown that DQA1*0501 was the most 
frequent HLA-DQA1 allele among © D M  patients (1996). They documented 
this allele in 72% of © D M  cases compared with 48% in controls and 
DQA 1*0301 in 45% of © D M  cases compared with 26% in controls (Izaabel et 
al., 1996). Lee et al. confirmed that DQA1*0301 and DQA1*0501 were 
positively associated with © D M  (1996).
Some HLA-DQA 1 alleles have been suggested to confer protection against 
©DM . Thus, DQA1*0102 and DQA1*0201 were negatively associated with 
© D M  in a study from Korea (Lee et al., 1996). Also DQA1*0103 has been 
described as protective from © D M  (Awata, Kanazawa, 1994).
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Table 7. HLA-DQA 1 alleles proposed to confer susceptibility to or protection against 
IDDM.
Susceptibility
*0301
*0501
Protection
*0102
*0103
*0201
2.4. HLA-DQ and HLA-DR allele combinations
Not just single alleles, but their combinations on chromosome six appear to be 
important for the susceptibility to or protection against IDDM (She, 1996). 
Recent studies have shown certain associations between certain combinations 
of different DRB1, DQA1, and DQB1 alleles and risk of IDDM. R0nningen 
and coworkers have reviewed the known associations of candidate class П sus­
ceptibility alleles with IDDM in five large racial groups: Caucasians, Asian 
Indians, Negroids, Japanese and Chinese (1991) (Table 8). It has been shown 
that susceptibility to IDDM was most strongly associated with a particular com­
bination of HLA-DQA 1 and HLA-DQB 1 alleles in different ethnic groups. 
DQA 1*0301 together with DQB 1*0302, and DQA 1*0501 together with 
DQB 1*0201 were found associated with IDDM susceptibility in Caucasians, 
Blacks and Japanese (R0nningen et al., 1991). HLA-DR3-DQA 1*0501- 
DQB 1*0201/HLA-DRB 1*0405-DQA 1*0301-DQB 1*0302 appears to be the 
strongest susceptibility genotype in Caucasians with IDDM, carrying relative 
risk between 20 and 45 (Van der Auwera et al., 1995; Sanjeevi et al., 1996). 
Caillat-Zucman studied Caucasian IDDM subjects and healthy controls for 
DRB 1*03, DRB 1*04, DQB 1*0201, DQB 1*0302, DQA 1*0301, and 
DQA1*0501. The highest relative risk was observed in patients carrying both 
the DRB 1*03-DQB 1*0201 and the DRB 1*0402 or DRB 1 *0405-DQB 1 *0302 
haplotypes (1992). The most frequent genotypes in IDDM cases in Spain were 
DR3-DQB 1*0201-DQA 1*0501 and DR4-DQB1 *0302-DQA 1*0301 (Serrano- 
Rios et al., 1996). Tait and colleagues have found that 95% of DRB 1*0401 
IDDM subjects were also DQB 1*0302 positive (1995). Heimberg’s group 
detected that DQA 1 *0301-DQB 1*0302/DQA 1*0501-DQB 1*0201 genotype 
was present in 30% of the IDDM patients and only in 1% of the typed healthy 
controls, resulting in a relative risk of 35 (1992). Lampasona and coworkers 
have shown that 88% of IDDM patients from Northem-Italy and 20% of 
unrelated control subjects had either HLA-DQA 1*0501-DQB 1*0201 or 
HLA-DQA 1*0301-DQB 1*0302 in the absence of HLA-DQA 1*0102- 
DQB 1*0602 (1995). In Japanese IDDM patients DRB 1*0405-DQA 1*0301-
22
DQB 1 *0401, DRB 1 *0901-DQA 1*0301 -DQB 1 *0303 and DRB 1 *0802- 
DQA 1*0301-DQB 1*0302 were the major susceptibility haplotypes (Awata and 
Kanazawa, 1994). In a Korean study DQA 1*0301-DQB 1*0201, DQA 1*0501- 
DQB 1*0201 and DQA 1*0501-DQB 1*0302 were positively and DQA 1*0102- 
DQB 1*0601 negatively associated with IDDM. The frequencies of DR3- 
DQ A 1*0301 -DQB 1 *0201 and DR3-DQA1 *0501 -DQB 1 *0201, DR4- 
DQA 1*0301-DQB 1*0201 and DR9-DQA 1*0301-DQB 1*0303 were signifi­
cantly higher in IDDM patients (Lee et al., 1996).
Table 8. HLA-DR-DQ allele combinations proposed to confer susceptibility to or 
protection against IDDM.
Susceptibility 
DRB1
*0401
*0402
*0405
*03
*03
*04
*0405
Protection
DRB1 DQAl DQBl
*0102 *0601
*0102 *0602
*0403 *0501 *0301
*15 *0102 *0602
*15 *0103 *0602
As with single alleles, some allele combinations have been shown to confer 
protection against IDDM. Protection against IDDM is usually associated with 
HLA-DQB 1 *0602, in any allele combination. Resistance against development 
of IDDM has been found with HLA-DQA 1*0102-DQB 1*0602, less protection 
was associated with HLA-DRB 1*0403-DQA 1*0501-DQB 1*0301 (Van der 
Auwera et al., 1995). The major protective effect for IDDM in the population 
of Swedish children is conferred by the DR 15-DQA1*0102-DQB 1*0602 haplo- 
type in a dominant manner. The DQB 1 *0602 was the allele most likely to be 
responsible for the protective effect of this haplotype, although an effect of the 
DR15 allele could not be excluded (Kockum et al., 1995). DRB 1*1501- 
DQA1*0103-DQB 1*0602 and DRB 1*1502-DQA1*0103-DQB 1*0601 are the 
major resistance haplotypes in Japan (Awata and Kanazawa, 1994).
DQAl DQBl
*0301 *0201
*0301 *0302
*0301 *0501
*0501 *0201
*0501 *0302
*0302 
*0302 
*0302
*0501 *0201
*0301 *0201
*0301 *0201
*0301 *0302
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PURPOSE OF THE STUDY
This study was undertaken to establish the prevalence of some suggested 
immune and genetic factors associated with IDDM in Estonia in
1) newly diagnosed childhood onset IDDM patients,
2) healthy siblings of IDDM patients,
3) control group.
The specific aims of the study were:
1. To establish the prevalence of ICA, GADA and IA-2A in study groups.
2. To learn the frequency of selected HLA-DQ alleles associated with 
IDDM and their combinations in Estonian IDDM patients and control 
group, also the concomitant risk of IDDM.
3. To follow for three years the siblings of IDDM patients, initially investi­
gated for the immune and genetic factors, for the development of IDDM.
4. To parallel the data from Estonia with that in other populations.
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MATEMAL AND METHODS
1. Study subjects
1.1. Childhood onset IDDM patients
Group one
Consecutive 29 newly diagnosed IDDM children under the age of 15 in Estonia 
in 1993-1994, were included in the study. The age ranged from two to 14 years 
(mean 7.9±3.8). The group consisted of 11 girls (37.9%) and 18 boys (62.1%). 
Blood specimens for the detection of autoantibodies was taken during the first 
week after the diagnosis.
Group two
Two hundred invitation letters were mailed to the patients from the Estonian 
Childhood Onset IDDM Registry (VI) in 1990. Ninety-seven patients re­
sponded and were recruited for the genetic investigation. The Estonian Child­
hood Onset IDDM Registry contains information on the cases diagnosed since 
1980. It is at least 95% complete. This group consisted of 53 females (54.6%) 
and 44 males (45.4%) who had developed IDDM at less than 15 years of age 
(age at diagnosis 0-14 years, mean age 7.5±3.8). This group provided blood 
specimens for the detection of HLA-DR and HLA-DQ locus alleles.
1.2. Healthy siblings of childhood onset IDDM patients
Healthy siblings of IDDM cases from the Estonian Childhood Onset IDDM 
Registry were invited to participate in the study by mail in 1994. One hundred 
invitation letters were mailed to the families with an IDDM child. The consent 
to participate was received from 44 families. Seventy-one siblings from these 
families were included in the study. The prevalence of autoantibodies and 
HLA-DR and HLA-DQ locus alleles was estimated in them. There were 
32 boys (45.1%) and 39 girls (54.9%) in this group, age two to 24 years (mean 
10.2±4.8).
The same siblings were contacted in December 1997 by mail. Their status as 
for clinical IDDM was learned.
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1.3. Controls
Group one
This group consisted of 614 non-diabetic kindergarten and schoolchildren, 
314 girls (51.1%) and 300 boys (48.9%), age 3-18 years (mean 10.1±4.2). 
Children were chosen from six different regions of Estonia (Tallinn, Tartu, 
Paide, Põlva, Nõo and Jõgeva) to determine the prevalence of ICA and GADA. 
The age distribution of this group was following — 3-5 years (118), 6-8 years 
(131), 9-11 years (119), 12-14 years (124), 15-18 years (122). Samples from 
614 healthy nondiabetic children and adolescents were analyzed in 1991 for 
ICA and GADA. In 1994 only those positive for ICA in the initial 1991 sample 
were retested for ICA and GADA.
Group two
One hundred and three first year medical students from the University of Tartu 
(mean age 20.5±1.7) and 166 healthy blood donors (mean age 32.4±11.2) 
provided blood for the assessment of the HLA-DR and HLA-DQ locus allele 
frequencies in the Estonian population.
2. Detection of antibodies
2.1. Islet cell antibodies
ICA were determined by a standard immunofluorescence method. Fluorescein- 
conjugated rabbit antihuman IgG (Behringwerke, Marburg, Germany) was used 
to detect ICA. Both laboratories participate in the international ICA Standardi­
zation Workshop. Endpoint dilution titers for all positive samples were 
expressed in JDFU relative to the above mentioned international reference stan­
dard. The detection limit was 2.5 JDFU. Assay sensitivity was 100%, specific­
ity 98%, validity 98% and consistency 98% (Karjalainen, 1990). Three inde­
pendent observers read the results.
2.2. Glutamic acid decarboxylase antibodies
GADA were measured according to the quantitative immunoprécipitation radi­
oligand method described by Petersen et al. (1994). Human recombinant islet 
GAD65 cDNA was transcribed and translated in vitro according to the manu­
facturer’s instruction (Promega, Madison, WI). The translation of transcribed 
RNA was performed in a methionine free rabbit reticulocyte lysate (Promega,
26
USA) in the presence of 35S-methionine (Amersham International, UK). Ali­
quots containing approximately 30,000 cpm of labeled GAD65 were incubated 
overnight at 4°C with serum (final dilution 1:25) in a total volume of 50 |il. 
Competition analysis was carried out by adding an excess of cold purified 
recombinant GAD65. The immune complexes were isolated by adding 7.5 mg 
of protein A-Sepharose (Pharmacia, Sweden) to each tube. After incubation for 
two hours at 4°C the reaction volume was transferred to a 96-well filtration 
system. The units were placed on a vacuum device allowing rapid washing. 
After ten washes, the bottom of each well in the filtration units was punched 
into tubes. Subsequently 2.5 ml of scintillation fluid was added to each tube. 
The radioactivity was measured in the scintillation counter. The results were 
expressed in relative units (RU) representing specific binding as a percentage 
of that obtained with a positive standard serum. The cutoff limit for GADA 
positivity was set at 7.7 RU. The sensitivity of the assay was 80%, the 
specificity 94% based on the 101 samples included in the second international 
GADA workshop (Schmidli et al., 1995).
2.3. Tyrosine phosphatase antibodies
IA-2A were measured by radioimmunoassay (Wiest-Ladenburger et al., 1997). 
Plasmid cDNA of full-length IA-2 and cDNA encoding for the cytoplasmic part 
of IA-2 (aa 603-979) were cloned into the pSP64poly(A)-vector and were 
amplified in Escherichia coli XL 1 blue and isolated by a QLAprep spin plasmid 
miniprep kit (QLAGEN, Germany). cDNA was transcribed into RNA and then 
translated into protein in the presence of 35S methionine (40 |iCi; 1,000 
Ci/mmol, Amersham, Germany) using a SP6 coupled reticulocyte lysate system 
(Promega, Madison, WI). Protein-bound radioactivity was separated by gel 
filtration on Sephadex G25 columns (Pharmacia, Germany). 2.5 fil of serum 
was incubated in duplicates with 20,000 cpm of radioactive protein in 50 \x\ 
immunoprécipitation buffer in round-bottom microtiter wells at 4°C overnight. 
One |iig of swollen prewashed protein A sepharose (Pharmacia, Sweden) was 
diluted in 50 fil of immunoprécipitation buffer and was incubated with samples 
for one hour at 4°C. Protein A Sepharose-bound immune complexes were sepa­
rated from unbound protein by washing 10 times with 150 |il of immuno­
précipitation buffer in membrane bottomed microtiter wells and transferred to 
scintillation vials. Counts per minute were determined in a beta counter. Quan­
tification was achieved by including a standard dilution curve on each 
microtiter plate. For recently identified autoantigen IA-2, human monoclonal 
antibodies were not available. The quantification of IA-2A had to be performed 
relative to a positive-reference serum with unknown concentration of specific 
antibody. Selected reference sera was taken from a patient with newly diag­
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nosed IDDM, which revealed an identical titer of IA-2A. Results were ex­
pressed in arbitrary units (AU). The radioactivity precipitated by a 1:8 dilution 
of the standard was set at 10 U, as this dilution was in the linear range of the 
standard curve in all established assays. IA-2A assay had the sensitivity of 
62.7% and specificity of 93.1%.
3. Detection of HLA-DQ and HLA-DR alleles
3.1. Extraction of DNA
DNA was extracted from peripheral blood using the protocol of DNA salt 
extraction by Gustincich (1991). One ml of red cell lysis buffer was added to 
EDTA-blood, rotated for 10 minutes and leucocytes/nuclei spinned down by 
centrifuge at 10 minutes at 3500 rpm. Washing steps were repeated until the 
pellet was white and the pellet resuspended by adding three ml Proteidae 
K-lysis buffer. After overnight incubation at 37°C, one ml of saturated NaCl 
(~6M) was added at room temperature, tubes shaken vigorously and precipi­
tated proteins spinned down for 15 minutes at 3500 rpm. The supernatant was 
poured into new polypropylene tubes and two volumes of cold absolute ethanol 
added. Tubes were inverted gently until DNA precipitated out in the form of a 
white stringy mass. Using a Pasteur pipette which tip had been heated to form a 
hook, DNA was picked up and washed once in 90% ethanol to remove traces of 
salt. Finally DNA was resuspended in a small volume 200 |il of TE buffer and 
incubated at 65°C until DNA was dissolved. The purity and concentration of 
DNA was estimated by spectrophotometric method. The readings of optical 
density were taken at wavelengths 260 nm and 280 nm.
3.2. Detection of alleles
The HLA-DQ alleles suggested associated with low or high IDDM risk were 
determined using two steps (Sjöroos et al., 1995). The samples were first 
studied for the presence of the DQB 1*0201, *0301, *0302 and *0602/0603 
using a method based on binding of the biotinylated amplification product onto 
streptavidin coated microtiter plate wells, followed by hybridization with lan­
thanide labeled oligonucleotide probes. The fluorescence properties of the 
different lanthanides (europium, samarium and terbium) allowed simultaneous 
detection of three different reaction products in a single microtiter plate well 
with time-resolved fluorometry (Sjöroos et al., 1995).
All samples positive for HLA-DQB1 *0302 were selected for the further 
DR4 subtyping which was carried out by genomic amplification in two po­
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lymerase chain reactions (PCRs), with the primer sequences as defined by 
Olerup and Zetterquist (1992). Primers permitted to detect DRB 1*0401, *0402, 
*0403, *0404, *0405, *0408 alleles.
Samples positive for DQB 1*0201 were further studied for DQA 1*0501 and 
*0201 alleles. This assay was based on a modified method where biotinylated 
sequence specific probes and an europium labeled detection probe was utilized 
(Sjöroos et al., 1996).
All samples that were found positive for both HLA-DQB 1*0301 and *0302 
in the screening test were later reanalyzed for the presence of the DQB 1 *0304 
allele using sequence specific primers described by Olerup and colleagues 
(1993).
4. Statistical methods
For normally distributed continuous variables the mean (M) and the standard 
deviation (SD) were calculated. A chi-square test with Yates correction or two- 
sided Fisher’s exact test when appropriate were used for the detection of 
significant differences in the prevalence of alleles and antibodies between study 
groups. Correlations between antibodies and other parameters were analyzed by 
the Spearman’s test. Statistical significance was assumed at p less than 0.05.
Odds ratio (OR) was calculated according to the formula (a x d / b x c) where a 
and b are the numbers of the IDDM patients that were positive and negative for 
the marker, respectively, and с and d, the respective numbers of control 
subjects. Haldane’s correction for small samples was used when appropriate. 
Correction of the acceptance p level (0.05) was performed by the Bonferoni 
method for multiple comparisons (Armitage and Berry, 1994).
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RESULTS AND DISCUSSION
1. Immune factors of IDDM
1.1. Antibodies in newly diagnosed childhood onset IDDM patients
All three antibodies (ICA, GADA and IA-2A) were measured in 29 newly 
diagnosed childhood onset IDDM cases (V). The values of individual cases are 
given in Table 9. Table 10 summarizes the prevalence of the different anti­
bodies in newly diagnosed IDDM group.
Table 9. Individual values of ICA (JDFU), GADA (RU) and IA-2A (AU) in newly 
diagnosed childhood onset IDDM patients
ID Sex Age ICA GADA IA-2A
E01 m 8 40 60.2 0
E02 m 3 20 0 83.1
E03 m 3 80 14.1 29.6
E04 m 7 80 61.4 0
E05 m 12 5 0 0
E06 m 14 20 0 4.7
E07 f 14 0 48.6 0
E08 m 9 0 0 0
E09 f 5 20 0 0
ЕЮ m 14 >160 0 0
E ll m 9 >160 76.5 103.4
E12 f 11 2.5 0 0
E13 m 6 5 76 0
E14 m 5 >160 109.3 0
E15 f 6 20 0 0
E16 f 9 80 0 109.5
E17 m 11 5 0 0
E18 m 3 20 0 70.2
E19 m 12 >160 92.6 65.3
E20 f 4 80 44.1 73.3
E21 f 3 80 0 0
E22 m 4 0 0 8.5
E23 f 8 2.5 0 0
E24 f 9 40 0 0
E25 m 13 40 83.6 0
E26 f 2 0 0 0
E27 m 6 >160 107.9 9.7
E28 m 0 0 0 0
E29 f 10 0 0 0
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Twenty-three IDDM patients out of 29 (79.3%) were positive for ICA at the 
first week after diagnosis, 15 boys and eight girls. Three boys and three girls 
did not have detectable ICA. The range of ICA level in this group was from 2.5 
to more than 160 JDFU. The median value of the whole group was 20 JDFU. 
Eighteen (78.3%) among the 23 ICA positive individuals had the titer greater 
than or equal to 20 JDFU, ten (43.7%) had the titer greater than or equal to 
80 JDFU. Five children (21.7%), all boys, expressed a very high titer of ICA, 
greater than or equal to 160 JDFU. The association between ICA and age 
(r=-0.09) was weak in this cohort, between ICA and sex (r=-0.30) — moder­
ately stronger.
Table 10. Prevalence of ICA, GADA and IA-2A in newly diagnosed childhood onset 
IDDM patients (IDDM), healthy siblings of IDDM patients (Siblings) and controls 
(Controls)
Antibody IDDM
N=29
Siblings
N=71
Controls
N=614
n % n % n %
ICA 23 79.31’2 5 7.0 10 1.6
ICA>20 JDFU 18 62.71’2 5 7.0 6 1.0
ICA>80 JDFU 10 34.51’2 5 7.0 2 0.3
ICA>160 JDFU 5 17.22 5 7.0 0 0.0
Only ICA 9 31.012 1 1.4 0 0.0
GADA 11 37.92 12 16.93 14 2.3
ICA and GADA 10 34.52 4 5.6 5 0.8
IA-2A 10 34.5 4 5.6 ND ND
ICA and IA-2A 9 31.0 3 4.2 ND ND
ICA, GADA and IA-2A 5 17.22 3 4.2 ND ND
GADA and IA-2A 5 17.2 4 5.6 ND ND
GADA and/or IA-2A 16 55.2 12 16.9 ND ND
ICA and GADA and/or IA-2A 14 48.31 5 7.0 ND ND
At least one antibody 25 86.2 13 18.4 19 3.1
No antibodies 4 13.81'2 58 81.63 595 96.9
1 Statistically significant difference (p<0.05) between IDDM and Siblings 
Statistically significant difference (p<0.05) between IDDM and Controls 
3 Statistically significant difference (p<0.05) between Controls and Siblings 
ND — not detected
GADA were found in this group about twice less frequently than ICA. Only 11 
(37.9%) of newly diagnosed IDDM cases tested positive for GADA. Nine of 
the eleven GADA positive individuals were males. The positive range was from 
14 to 109 RU. The median value was 76 RU among those with GADA. The 
association between the presence of GADA and age (r=0.01) was very weak, 
with sex (r=-0.32) somewhat stronger.
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Ten children (34.5%) out of 29 had detectable IA-2A at the diagnosis of 
IDDM. Again the boys were more prone to express humoral autoimmunity. 
Eight boys and only two girls had IA-2A. The positive range was from 4.7 to 
109.5 units, the median value 68 AU among those. The correlations between 
antibody positivity and sex (r=-0.27) and age (r=-0.23) were low.
All three antibodies were posi
n=23ICA
n=10 n=11
Figure 1. Concurrence of ICA, GADA and 
IA-2A in 29 newly diagnosed childhood onset 
IDDM patients
tive only in five children with newly 
diagnosed IDDM (17.2%) and none 
were positive in four (13.8%) 
children. At least one antibody was 
positive in 25 (86.2%) of newly 
diagnosed patients. Nine (31.3%) 
had double antibody positivity. 
GADA and/or IA-2A were positive 
in 16 cases out of 29 (55.2%), 14 of 
these 16 were also ICA positive. The 
correlation between antibodies of 
newly diagnosed IDDM patients 
was low, between ICA and GADA 
(r=0.22), between ICA and IA-2A 
(r=0.37), between GADA and 
IA-2A (r=0.18).
1.2. Antibodies in healthy siblings of childhood onset IDDM patients
We studied 71 healthy siblings of childhood onset IDDM patients for the 
prevalence of IDDM related antibodies (V) (Table 10). The individual results of 
any antibody positive individuals are given in Table 11.
The frequency of ICA was 7.0% in healthy siblings С in five individuals out 
of 71. Four of them were females and one was male. All ICA positive individu­
als had a very high titer of antibodies С greater than or equal to 160 JDFU. 
Twelve siblings (16.9%) had detectable GADA that exceeded the prevalence of 
ICA more than twice. The titer of GADA among them ranged from 10.7 to 
115.3 RU. GADA were found among males and females with similar frequency. 
The GADA positive group consisted from five females and seven males. The 
highest GADA titers were documented in females in this group.
32
Table 11. Individual values of ICA (JDFU), GADA (RU) and IA-2A (AU) in antibody 
positive healthy siblings of IDDM patients.
ID Sex ICA GADA IA-2A
7a f 0 115.3 0
13a m 0 10.7 0
13b m 0 39.9 0
16a m 0 63.1 0
16b m 0 10.7 76
17a f >160 84.6 0
19a m 0 74.6 0
20a f >160 78.5 94
25a m 0 65 0
32a f >160 90.6 100
35a f 0 45 0
37a f >160 0 0
39a m >160 68 95
IA-2A was the least frequently 
found antibody studied by us. 
These were found in four (5.6%) 
siblings. Two males and two fe­
males were LA-2A positive. All 
four had high levels of IA-2A, 
exceeding 75 AU. We found that 
most of the healthy siblings С 58 
(81.6%) С did not have any of the 
three studied antibodies. Among 
the 13 antibody positive individuals 
(18.3%), 12 tested positive for 
GADA (Figure 2). All three anti­
bodies were positive only in three 
Figure 2. Concurrence of ICA, GADA and (4 .2%) siblings. Four siblings out 
IA-2A in 71 healthy siblings of childhood 0f fjve j c a  positives had also 
onset IDDM patients GADA and/or IA-2A.
Table 12. Correlation coefficients between sex, age and IDDM-related antibodies in 
healthy siblings of childhood onset IDDM patients
Sex Age ICA GADA
ICA 0.14 0.11 0.46
GADA -0.12 0.04 0.46
IA-2A -0.02 0.18 0.65 0.54
ICA n=5
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In the healthy siblings group the correlation between different antibodies was 
stronger than in the newly diagnosed childhood onset IDDM group (Table 12). 
The correlation between ICA and IA-2A was the strongest (r=0.65), followed 
by the one between GADA and LA-2A (r=0.54) and ICA and GADA (r=0.46).
1.3. Antibodies in controls
The analysis of the prevalence of IDDM associated antibodies in controls was 
performed in 614 children and adolescents (I, V). Nineteen of the 614 tested 
individuals (3%) were either ICA and/or GADA positive (Table 10, Table 13).
Table 13. Individual values of ICA (JDFU) and GADA (RU) in antibody positive 
individuals from the control group in 1991 and 1994. IDDM+ individuals developed 
IDDM between the two investigations.
ID Sex Age ICA GADA IDDM
1991 1994 1991 1994
9 f 6 0 0 9.5 0
23 f 11 0 0 97.7 0
27 m 13 97 ND 129.3 ND +
32 m 15 3 0 2.4 0.3
60 m 15 0 0 11.9 0
89 f 16 18 ND 125.9 ND +
121 f 17 18 0 8.8 4.3
141 f 10 0 0 12 0
177 m 6 0 0 7.7 0
257 m 15 0 0 9.6 0
259 m 14 0 0 7.8 0
268 f 17 0 0 154.2 0
301 f 11 65 18 4.3 2.7
369 f 11 0 0 7.8 0
390 f 9 34 0 2.3 3.8
405 f 10 81 18 123 80.4
537 m 11 50 5 8.5 0.6
570 f 3 34 36 4.9 0.9
588 m 4 3 0 3.8 1.4
ND — not detected
Ten children out of 614 tested positive for ICA (1.6%). The levels of ICA in the 
ICA positive subjects ranged from three to 97 JDFU, median 42 JDFU. Six 
children had ICA levels higher than 20 JDFU. Two of the six had the ICA level 
higher than 80 JDFU. We did not find any differences in ICA frequency 
between males and females (p=0.188) or between those younger and older than 
10 years of age (p=0.333).
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GADA were found more often in this group compared with ICA. Fourteen 
children out of 614 (2.3%) had detectable GADA. There was no significant 
difference in the frequency of GADA between boys and girls and between 
those younger and older than 10 years.
Five subjects tested positive for both antibodies (0.8%). The frequency of 
double antibody positivity was significantly lower than for GADA or ICA alone 
(p=0.03). The correlation between GADA and ICA levels was moderate 
(r=0.43).
ICA and GADA were tested 
three years later, in 1994, only in 
initially ICA positive individuals. 
Four individuals out of ten re­
mained positive for ICA in the 
repeated testing but their antibody 
levels decreased almost statistically 
significantly from the median of 
42 JDFU to 18 JDFU (p=0.06). The 
median GADA level decreased sig­
nificantly from 4.9 to 1.4 RU 
(p=0.04). Those children who re­
mained ICA positive had the initial 
level of ICA greater than 20 JDFU. 
Among the four children initially 
positive for both antibodies, only 
one remained double positive, one was ICA positive at repeated testing and two 
did not have any antibodies.
The boy (case 27) with the highest ICA titer (97 JDFU) and highest GADA 
level (129.3 RU) was diagnosed with IDDM four months after the first 
sampling. Another child (case 89) with GADA 123 RU and ICA 18 JDFU 
developed diabetes two years after the first testing in 1991.
ICA (JDFU)
Year
Figure 3. Values of ICA (JDFU) in antibody 
positive individuals from the control group, 
1991 and 1994.
1.4. Discussion
Our study describes the prevalence of various autoantibodies associated with 
IDDM in Estonia, including ICA, GADA, IA-2A. Although ICA were de­
scribed already in 1974, data on the prevalence of these antibodies are still 
missing for many populations. Data from Estonia are of particular interest as 
Estonia is geographically close to Finland, the country with the highest inci­
dence of IDDM in the world.
The prevalence of the antibodies first described in IDDM patients, ICA, was 
the highest in the newly diagnosed IDDM group, 79.3%. The prevalence of ICA
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in Estonian newly diagnosed © DM  patients was comparable to other studies 
from Europe. Thus, the prevalence of ICA in Finland has been reported to be 75% 
(Karjalainen et al., 1986), in Germany 75% (Wiest-Ladenburger et al., 1997), in 
Italy 89% (Genovese et al., 1992), in Sweden 81% (Landin-Olsson et al., 1989), 
in Belgium 73% (Gorus et al., 1997). Data from Estonia confirm that most but not 
all newly diagnosed IDDM patients have detectable ICA.
%
100 
80 
60 
40 
20 
0
Figure 4. Prevalence (%) of ICA, GADA and IA-2A in newly diagnosed childhood 
onset IDDM patients (IDDM), healthy siblings of IDDM patients (Siblings) and controls 
(Controls)
The prevalence of ICA in Estonian siblings of IDDM patients is one of the 
highest reported until now in Europe. ICA were found in 7% of siblings of 
IDDM patients. The ICA prevalence in healthy siblings group was similar to 
that in Germany 6.9% (Seissler et al., 1996), and higher than in France 5.1% 
(Thivolet et al., 1988) and Belgium 5% (Gorus et al., 1997). It has to be 
considered that all these data including ours are based on comparatively small 
numbers of subjects and the choice of the individuals might have had influence 
on the outcome.
The prevalence of ICA in the controls, aged 3-18 years, was 1.6%. Approxi­
mately, a tenfold difference has been found in the prevalence of ICA between 
European populations. ICA has been found in 0.4% to 4.1 % of healthy general 
population. Estonian data are similar to the ones from France, both as to the 
prevalence of ICA and the incidence of IDDM (Levy-Marchal et al 1992; 
Green et al., 1992; I).
79.3
IDDM Siblings Controls
]  ICA Щ GADA ■  IA-2A
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P r e v a le n c e  of IC A
Figure 5. Annual incidence of childhood onset IDDM (per 100,000) and prevalence (%) 
of ICA in the young background population of selected countries, and the linear 
regression line.
The prevalence of ICA in the control group was about twelve times more than the 
prevalence of IDDM in Estonia in the respective age group. This indicates that 
the great majority of those positive for ICA will not progress to clinical IDDM. 
That was also confirmed by the decrease in the prevalence of ICA and their titer 
at the repeated investigation. Based on available data, we have compared the 
frequency of ICA in the young background populations in a series of six countries 
with the incidence of childhood onset IDDM in those countries (I). It appears 
there is a highly significant correlation (r=0.97, pcO.Ol), indicating that the 
proportion of ICA-positive children progressing to clinical disease is similar in 
different populations. That means the variation in disease incidence between 
countries can be partly explained by the frequency of ICA positivity in the non­
diabetic population (I). In comparison with other populations, the prevalence of 
ICA in Estonian controls and the incidence of IDDM are intermediate.
The repeated testing of ICA in individuals positive for this antibody from 
the control group after three years showed a considerably reduced frequency. 
Of the eight repeatedly tested IDDM-free individuals, in three ICA had disap­
peared, and the titer was reduced in four. Only in one individual was seen a 
slight increase in the titer of ICA. The observation that about half of those 
testing positive for ICA in the initial sample did not have detectable antibodies 
three years later illustrates that ICA-positivity is often transient in nondiabetic 
children. High ICA level tends to be persistent more often than low level. Two
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of the ten individuals testing positive for ICA in 1991 developed IDDM during 
the three following years. The titer of ICA in one of these cases exceeded 
80 JDFU, in the second case it was not high, 18 JDFU. Few investigators have 
studied repeatedly the frequency of ICA in ICA positive individuals from the 
young background population. Repeated testing for ICA in other populations 
has given similar results, but decrease of antibody positivity was not so remark­
able as in our study. It may be explained by a shorter interval to the repeated 
investigation (Karjalainen, 1990; Levy-Marchal et a i,  1992; Bingley et al.,
1993). Our data confirm that the prognostic value of ICA positivity for the 
development of IDDM is low.
Our findings on the prevalence of GADA are of interest in several respects. 
The prevalence of GADA among newly diagnosed IDDM patients was low, 
only 37.9% in contrast to the reports from literature. In some countries the 
prevalence of GADA at the time of diagnosis has even exceeded 80% — in 
Germany 87% (Seissler et al., 1996), in Belgium 82% (Gorus et al., 1997). In 
Latvia the prevalence was 67% (Shtauvere et al., 1997). The reason for such a 
low frequency of these antibodies in Estonia could be methodological differ­
ences.
On the other hand, the prevalence of GADA in our healthy siblings cohort 
was higher (16.9%) than documented in other studies. The figure from our 
study was even higher than for Finland. Thus, in Finland the frequency of 
GADA in siblings was 9.6% (Kulmala et al., 1995), in Germany 6.4% (Wiest- 
Ladenburger et al., 1997). GADA were found in our siblings group twice as 
often as ICA and IA-2A. Our finding might be explained by the selection 
methods.
The frequency of GADA in the controls (2.3%) was similar to that of ICA. 
The frequency of GADA was similar to ours in Denmark, 2.5% (Petersen et al.,
1994) and Italy 2.1% (Velluzzi et al., 1997). The highest prevalence of GADA 
has been reported in the state of Washington — 4.6% (Leech et al., 1995).
The repeated tests of GADA in ICA positive individuals from the general 
population three years later showed that like ICA, also GADA levels and 
frequency tend to diminish. Three out of four seroconverted to GADA-negativ- 
ity including one with a very high initial level. Only one individual remained 
positive in repeated testing in 1994. This shows that transiently strong humoral 
responses to GAD can be seen in normal children. Our observation lends sup­
port to the view that GADA levels fluctuate and a possibility of transient, 
relatively meaningless for the development of IDDM, positivity of GADA in 
general population.
The investigation carried out by us is one of the few to study the prevalence 
of IA-2A in the IDDM cohort. The method for the detection IA-2A was intro­
duced only in 1990 and there are few reports on the association of IA-2A and 
IDDM. We found the prevalence of IA-2A of 34.5% among the newly diag­
nosed IDDM cases. These figures are somewhat lower than reported for other
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European populations — in Germany 73% (Wiest-Ladenburger et al., 1997), in 
Italy 58% (Gorus et al., 1997), but close to data from Japan — 41% (Kawasaki 
et al., 1997) and neighboring Latvia — 41% (Shtauvere et al., 1997).
We investigated also the frequency of IA-2A in healthy siblings of IDDM 
patients. IA-2A were found in 5.6% of the healthy siblings of IDDM cases. The 
frequency of these antibodies was somewhat higher than reported in other 
European studies. Two of the three siblings of IDDM cases who later developed 
IDDM, had detectable IA-2A.
We did not find any strong correlations between the prevalence of ICA, 
GADA, IA-2A and sex or age, although some studies have seen such relation­
ships (Schmidli et al., 1994; Petersen et al., 1994; Seissler et al., 1996). Most 
studies, similar to ours, have not found associations of ICA, GADA with sex or 
age (Christie et al., 1993; Grubin et al., 1994; Roll et al., 1994). Only moderate 
relationship among the three measured antibodies was found among the siblings 
of individuals with IDDM, but not in the newly diagnosed IDDM group. That 
may be explained by the small number of investigated patients. A number of 
studies have investigated the relationship between ICA, GADA and IA-2A. 
Strong association between IA-2 A, GADA and ICA has been observed in some 
studies, in particular with high levels of ICA (Christie et al., 1993; Bonifacio et 
al., 1995; Ongagna et al., 1995; Lan et al., 1996; Seissler et al., 1996). No 
correlation was found in the same antibody levels (Gorus et al., 1997).
2. Genetic factors of IDDM
2.1. Selected HLA-DQB1 alleles in childhood 
onset IDDM patients and controls
The data of HLA-DQB 1 alleles and their combinations with other HLA alleles 
(II, П1, IV, V) is presented in Table 14 and Table 15.
Table 14. Prevalence of selected HLA-DQB 1 alleles in the childhood onset IDDM 
patients (IDDM) and controls (Controls)
Allele IDDM Controls OR
n % n %
*0201 53 54.6 84 31.2 2.7*
*0301 10 10.3 89 33.1 0.2*
*0302 64 66.0 48 17.8 8.9*
*0304 5 5.2 2 0.7 7.3*
*0602/0603 2 2.1 119 44.2 0.03*
* OR statistically significantly different from 1 (p<0.05)
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Of the five analyzed HLA-DQB1 alleles (*0201, *0301, *0302, *0304 and 
*0602/0603), the most frequent in the IDDM group was *0302 (66%). The 
lence of this allele was considerably higher than in the control group (1 c), 
p<0.05. The next most common allele among the IDDM cases was *0201, present 
in 54.6% of IDDM cases, also occurring significantly more frequently than in the 
controls where its prevalence was 31.2%. Although rare among both IDDM cases 
and controls, the prevalence of the novel DQB 1*0304 (5.2%) was significantly 
higher among IDDM cases compared with the controls (0.7%) (p<0.05).
The highest risk for IDDM of the studied HLA-DQB 1 locus was conferred 
by *0302. The OR for was 8.9, p<0.05. DQB 1*0304 appeared to confer the 
second highest susceptibility to IDDM in Estonia (OR=7.3, p<0.05). 
DQB 1*0201 was also associated with significantly increased risk for the 
development of IDDM, OR — 2.7, p<0.05.
Alleles IDDM Controls OR
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0 .2*
8.9*
7.3*
0.03*
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13.9*
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Figure 6. Prevalence (%) of selected HLA-DQB 1 alleles and HLA-DQB 1-DQA1 and 
HLA-DQB 1-DRB1 allele combinations in the childhood onset IDDM patients (IDDM) 
and controls (Controls).
* OR statistically significantly different from 1 (p<0.05)
Two of the investigated HLA-DQB 1 alleles were significantly less frequent in 
IDDM cases in Estonia than in the controls— *0301 and *0602/0603. More 
than 44% of the Estonian population was positive for HLA-DQB 1*0602/0603.
DQB1*0201 
DQB1*0301 
DQB1*0302 
DQB1*0304 
DQB 1*0602/0603 
DQB1 *0201-DQA1 *0201 
DQB1*0201-DQA1*0501 
DQB1*0302-DRB1*0401 
DQB 1 *0302-DRB1 *0402 
DQB 1*0302-DRB1 *0403 
DQB1 *0302-DRB1 *0404 
DQB1 *0302-DRB1 *0405 
DQB 1 *0302-DRB1 *0408 
DQB 1 *0304-DRB1 *0408
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The prevalence of DQB1 *0602/0603 was about 20 times less among the IDDM 
group (2.1%) than in the controls, resulting in the OR of 0.03 (p<0.05). About 
one third of the Estonian population carried DQB 1*0301. This allele was more 
than three times less common (10.3%) in the IDDM group compared with con­
trols and appeared also to provide protection against IDDM, but not as strongly 
as *0602/0603. The OR for this allele was 0.2 (p<0.05).
2.2. Selected HLA-DQ and HLA-DR allele combinations 
in childhood onset IDDM patients and controls
We also studied the prevalence of different allele combinations and found that 
the frequency of four was significantly different between the IDDM patients 
and control group (Table 15).
Table 15. Prevalence of selected HLA-DQB1-DQA1 and HLA-DQB1-DRB1 allele 
combinations in IDDM patients (IDDM) and controls (Controls).
Allele combination IDDM Controls OR
n % n %
DQB1 DQA1
*0201 *0501 49 50.5 59 22.0 3.6*
*0201 *0201 3 3.1 40 15.0 0.2*
DQB1 DRB1
*0302 *0401 42 43.3 14 5.2 13.9*
*0302 *0402 1 1.0 4 1.5 0.7
*0302 *0403 0 0 3 1.1 0.4
*0302 *0404 18 18.6 24 8.9 2.3
*0302 *0405 2 2.1 1 0.4 5.6
*0302 *0408 0 0 3 1.1 0.4
*0304 *0408 5 5.2 2 0.7 7.3*
* OR statistically significantly different from 1 (p<0.05)
Of the allele combinations the most frequent among the IDDM patients from 
Estonia was DQB 1 *0201-DQA 1*0501 (50.5%). This allele combination was 
more than twice as common in IDDM cases compared with the general Esto­
nian population (22%), p<0.05. The combination conferred a moderately in­
creased risk of IDDM, OR of 3.6. It appeared that all Estonian IDDM cases that 
carried DQB 1*0201-DQA 1*0501 in our particular study were also positive for 
DQB 1*0302.
Of the two-allele combinations of the HLA-DQB1 and HLA-DRB1 alleles, 
the most common among IDDM patients was DQB 1*0302-DRB 1*0401. This 
two-allele combination was the second in frequency of those found in Estonian 
©DM  cases. It was present in 43.3% of IDDM cases and in only 5.2% of the
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controls. The OR for this combination was the highest in our study, 13.9 
(p<0.05). A high OR was also found for the two allele combination of 
HLA-DQB 1*0304-DRB 1*0408. The value of the OR was 7.3 (p<0.05), al­
though both alleles were uncommon in the © D M  (5.2%) and control group
(0.7%).
The combination of HLA-DQB 1*0201-DQA 1*0201 was significantly less 
common in IDDM cases compared with controls. The presence of this particu­
lar combination reduced the risk of IDDM about five times.
2.3. Discussion
We analyzed the prevalence of selected HLA-DQB 1 locus alleles proposed to 
be related to the protection against or susceptibility to IDDM in Estonia. The 
study carried out by us is one of the first to establish the frequency of certain 
HLA-DQ locus alleles in the Estonian population. This was necessary to find 
out the alleles associated with the risk of IDDM in Estonia. Our study showed 
that the main features of HLA-related IDDM susceptibility in Estonia were 
similar to those found in most other European studies.
The most common HLA-DQ alleles of the ones studied in the Estonian 
IDDM patients were DQB 1*0302 (66%) followed by DQB 1*0201 (54.6%), 
both non-Asp-57. These data agree with the numerous reports from literature 
where these two alleles have been recognized as the most important single 
alleles responsible for the susceptibility to IDDM (Saukkonen et al., 1998; 
Izaabel et al., 1996; Sanjeevi et al., 1995; Reijonen et al., 1994).
Increased risk of EDDM was conferred also by HLA-DQB 1 *0304, OR of
7.3. HLA-DQB 1 *0304 is a rare DQB 1*03 subtype that combines the features 
of both DQB 1*0301 and DQB 1*0302 alleles (Fenske and Baxter-Lowe, 1992). 
The first of the two alleles reduces the risk of IDDM while the second is an 
allele associated with and increased risk (Thorsby and Ronningen, 1993). HLA- 
DQB 1*0304 evidently also confers higher risk for IDDM. Although of interest, 
this finding should not be clinically overestimated as the frequency of the 
HLA-DQB 1 *0304 was only a low of 5.2% among IDDM cases and 0.7% in the 
controls. In a comparative study that allele yielded the OR of 4.2 in Latvians, 
3.6 in Russians (ПГ). HLA-DQB 1 *0304 was found as a very rare allele in 
North-American and German Caucasian population, but more commonly in 
Czech gypsies (Fenske et al., 1992; Tautz et al., 1992; Cerna et a i, 1992). In 
Sardinia it was associated with protection against IDDM (Cucca et al., 1993).
The least frequently found HLA-DQB 1 allele among Estonian IDDM pa­
tients was *0602/0603, the allele postulated to be protective against IDDM 
(Pugliese et al., 1995; Ilonen et al., 1996). Protective influences are thought to 
be superior to the susceptibility to IDDM conferred by other alleles (Caillat- 
Zucman et al., 1992; Lee et al., 1996; Yasunaga et al., 1996). The prevalence of
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this allele in IDDM patients was only 2.1%. Although significantly lowering 
the risk of IDDM, the presence of this allele does not provide complete protec­
tion against IDDM in Estonian population. Two of the 97 IDDM cases still had 
this protective allele. In these two particular instances the other alleles at the 
HLA-DQ and HLA-DR loci were DQB 1*0304-DRB 1*0408 and DQB 1*0302- 
DRB 1*0401, both conferring susceptibility to EDDM.
The DQB 1*0602/0603 allele was associated with the highest protection 
against IDDM of the investigated HLA-DQ locus alleles in Estonia. The factor 
of protection the presence of this allele conferred in Estonia was very high, 
about 38 (OR=0.03). The HLA-DQB1 *0602 has appeared as protective from 
most of the studies of diverse populations — Caucasians, Hispanics, Orientals, 
Negroids (Caillat-Zucman et al., 1992; Lee et al., 1996; Yasunaga et al., 1996). 
This allele has yielded OR-s of the magnitude of 0.12 among Finns (V), 0.15 
among Moroccans (Izaabel et al., 1996), 0.2 among Hispanics (Cruickshanks et 
al., 1994).
Remarkable differences in the incidence of IDDM have been found in neigh­
boring populations. The incidence of IDDM in Finland is 35 per 100,000 per 
year (Karvonen et al., 1993), in Estonia only 10 per 100,000 per year (VII). To 
clarify the IDDM incidence variation HLA-typing may add important informa­
tion. There are studies confirming the correlation between frequency of some 
HLA-DR, DQ alleles, their combinations and incidence of IDDM in different 
ethnic groups (Cruickshanks et al., 1994; Van der Auwera et al., 1995; She,
1996). The resistance against IDDM is often dominant over susceptibility (Van 
der Auwera et al., 1995; Ilonen et al., 1996). The high prevalence of the 
HLA-DQB 1 *0602/0603 in the population of Estonia and its high degree of 
protection against IDDM might be an important factor in explaining the consid­
erably lower incidence of IDDM in Estonia compared with Finland where the 
incidence is the highest in the world.
The most frequent allele combination among Estonian IDDM patients was 
DQB 1*0201-DQA 1*0501, in half the cases. Similar findings have been re­
ported in many other studies in Caucasians, Blacks and Japanese (R0nningen et 
a i,  1991; Lampasona et al., 1995; Van der Auwera et al., 1995; Serrano-Rios et 
al., 1996). The OR associated with these combinations was 3.6. Similar relative 
risk of 3-5 has been confirmed in the analysis IDDM susceptibility or resis­
tance in Black, Caucasian and Japanese subjects (Thorsby and R0nningen, 
1993).
The most frequently encountered HLA-DR4 subtype of the varieties studied 
in the Estonian DQB 1*0302 positive IDDM patients, was HLA-DRB 1*0401. 
This allele combination was eight times more frequent in IDDM patients 
(43.3%) compared with the controls (5.2%). The HLA-DRB 1*0401 allele has 
been found most frequently among IDDM cases also in Sweden and Norway 
(Sanjeevi et al., 1996; Yasunaga et al., 1996). The next most common allele 
combination was HLA-DQB 1 *0302-DRB 1 *0404, found in 18.6% of cases. The
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prevalence of this combination in cases was about twice higher than in the 
controls, but did not reach statistical significance.
The DQB 1*0304 concurred with DRB 1*0408 allele in all Estonian IDDM 
patients (Ш). The same finding was documented for cases from Latvia and 
Russia (Ш). The DQB 1 *0304-DRB 1 *0408 combinations were found only in 
three subjects from Northern America (in the remaining three DQB 1*0304 was 
associated with DRB 1*0403) and in one from Czech gypsies. In Sardinia, 
DQB 1*0304 was in combination with DRB 1*0403 (Fenske et al., 1992; Cerna 
et al., 1992; Cucca et al., 1993).
Of the allele combinations studied, four evolved as significantly associated 
with IDDM. Three of those were conferring susceptibility to IDDM and one 
protection. Our study confirms that the whole HLA-haplotype is important in 
the determination of the risk of IDDM, not just single alleles. The presence of 
HLA-DQA1*0201 in DQB 1*0201 positive individuals decreased the risk for 
the development of IDDM while the association with DQA 1*0501 increased 
the risk. Also, the combination of HLA-DQB 1 *0302 with different DRB 1 locus 
alleles produced varying results in the risk of IDDM. While DRB 1*0401 in­
creased the risk conferred by DQB 1*0302 alone, *0403 had a tendency to 
decrease the risk of IDDM.
3. Immune and genetic factors of IDDM in healthy siblings 
of childhood onset IDDM patients followed for three years
We followed the 71 healthy siblings of childhood onset IDDM patients for three 
years for the development of clinical IDDM. Three children (4%) were diag­
nosed with clinical IDDM by December 1997 (Table 16).
IDDM was diagnosed in case 16b six months after the investigation, in case 
17a nine months later and case 20a one and a half years later.
All three children, who developed later IDDM, had at least double antibody 
positivity at the time of the investigation. Two of them were double antibody 
positive (GADA/IA-2A and ICA/GADA) and one sibling had all three antibod­
ies detectable. One of the siblings carried DQB 1*0302-DRB 1*0401 allele com­
bination, the second and third DQB 1*0201-DQA 1*0501. Both these combina­
tions were found most often among Estonian IDDM patients. None of the al­
leles associated with protection against IDDM in Estonia were present in the 
three cases that went on to develop IDDM. After three years of follow-up, at 
the end of December 1997, the remaining two of the all antibody positive sib­
lings were still IDDM-free. Both siblings were positive for an allele that con­
fers protection against IDDM in Estonia, DQB 1*0301 and DQB 1*0602/0603.
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One of these two siblings is remarkably a dizygotic twin brother of the © DM  
case.
Table 16. Individual values of ICA (JDFU), GADA (RU) and IA-2A (RU) and occur­
rence of selected HLA-DR and HLA-DQ alleles in antibody positive healthy siblings of 
IDDM patients. IDDM+ individuals developed IDDM during the three-year follow-up.
ID ICA GADA IA-2A DRB1 DQAl DQBl IDDM
7a 0 115.3 0 *0501 *0201/
*0301
13a 0 10.7 0 *0401 *0501 *0201/
*0302
13b 0 39.9 0 *0401 *0302
16a 0 63.1 0 *0401/
*0404
*0302
16b 0 10.7 76 *0401 *0302 +
17a >160 84.6 0 *0501 *0201 +
19a 0 74.6 0 *0501 *0201
20a >160 78.5 94 *0501 *0201 +
25a 0 65 0 *0401 *0302
35a 0 45 0 *0501 *0201
32a >160 90.6 100 *0401 *0302/
*0602/
*0603
37a >160 0 0 *0602/
*0603
39a >160 68 95 *0401 *0301/
*0302
Our data corroborate that IDDM related antibodies are much more prevalent 
among first degree relatives of IDDM patients than general population and con­
sequently, they are at a higher risk for the development of © DM . An ICA level 
of 20 JDFU or more has been observed to be strongly predictive of progression 
to ©DM  in first-degree relatives of © D M  patients, with a progression rate of 
24-25% over five years (Riley et a l., 1990; Bonifacio et al., 1989). There are 
data suggesting that ICA are more predictive in first-degree relatives than in 
non-diabetic unrelated children (Levy-Marchal et al., 1992; Bingley et al.,
1993). The titer of ICA was very high in all five siblings from Estonia who 
were positive for ICA. The titer of ICA exceeded 160 JDFU in all of them. Two 
out of the five developed clinical © D M  shortly after investigation.
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CONCLUSIONS
1. The most frequent IDDM associated antibody in the newly diagnosed child­
hood onset IDDM patients in Estonia is ICA (79%) followed by lower 
prevalence of GADA (38%) and IA-2A (35%). The prevalence of ©DM 
associated antibodies among healthy siblings of IDDM cases was less and 
the lowest in the healthy controls.
2. The frequency of ICA in the young background population is closely associ­
ated with the incidence of childhood onset IDDM, r=0.97, p<0.05. The 
proportion of ICA-positive children progressing to IDDM is similar in dif­
ferent populations.
3. The most frequent of the studied HLA-DQB 1 alleles among Estonian IDDM 
patients is HLA-DQB 1 *0302 (present in 66%) followed by 
HLA-DQB 1*0201 (55%). Both these alleles were significantly more preva­
lent in the IDDM patients than in the controls.
4. The single HLA-DQB 1 allele carrying the highest risk for IDDM in Estonia, 
is HLA-DQB 1 *0302 (OR 8.9) followed by the novel HLA-DQB 1 *0304 
allele (OR 7.3).
5. The allele carrying the lowest risk of IDDM in Estonia is 
HLA-DQB 1*0602/0603. This allele is present in 44% of the Estonian 
healthy population. The risk of IDDM conferred by this allele is about four 
times less in Estonia than in Finland and this could partly explain the more 
than threefold difference in the incidence of IDDM between these two 
neighboring countries.
6. The most frequent double allele combination studied among Estonian IDDM 
patients is HLA-DQB 1*0201-DQA 1*0501, present in half the cases, and 
followed by HLA-DQB 1*0302-DRB 1*0401 (in 43%). This agrees with 
other studies in Caucasians.
7. The siblings of IDDM patients were at an increased risk of developing 
IDDM compared with the young background population. Four percent of 
siblings developed the disease during the three-year follow-up. Those who 
developed IDDM were all positive for at least two EDDM-related antibodies, 
including GADA, and carried the most frequent HLA double allele combi­
nations of Estonian IDDM patients.
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LAPSEEAS ALANUD INSULIINISÕLTUVA 
SUHKURTÕVE IMMUNOLOOGILISED JA 
GENEETILISED TEGURID EESTIS
Kokkuvõte
Insuliinisõltuv suhkurtõbi (ISST) on sageli lapseeas algav raske krooniline hai­
gus. Haiguse etioloogia ei ole senini teada. Seetõttu puudub ISST profülaktika 
võimalus. Viimase kahekümne aasta jooksul kogunenud andmed lubavad järel­
dada, et ISST tekib haigusele geneetiliselt vastuvõtlikel indiviididel auto- 
immuunse mehhanismiga. Paraku on immunoloogiliste ja geneetiliste tegurite 
seos ISST-ga komplitseeritud. Seetõttu on ISST etioloogia ja  patogeneesi pare­
maks mõistmiseks vaja uurida erisuguse geneetilise ja keskkondliku taustaga 
populatsioone. Praeguseni puudub Eestis informatsioon ISST-ga seotud immu­
noloogiliste ja  geneetiliste tegurite levimuse kohta.
Uurimuse eesmärgid
Ülaltoodust lähtudes oli käesoleva uuringu peaeesmärgiks kindlaks teha 
mitmete teadaolevate ISST-ga seotud immunoloogiliste ja  geneetiliste tegurite 
levimus järgmistes rühmades:
1) lapseeas alanud ISST-ga patsiendid,
2) lapseeas alanud ISST-ga patsientide terved õed-vennad,
3) kontrollgrupp.
Töö konkreetsed eesmärgid
1. Leida uuringurühmades Langerhansi saarekeste vastaste (ICA), glutamaadi 
dekarboksülaasi vastaste (GADA) ja türosiini fosfataasi vastaste antikehade 
(IA-2A) levimus.
2. Teha kindlaks HLA-DQB 1 lookuse ISST riskiga seotud alleelide ning mõne­
de teiste HLA-alleelide kombinatsioonide sagedus ISST-ga patsientidel ja 
kontrollgrupis, samuti nendega kaasnevad haiguse riskimäärad.
3. Jälgida ISST-ga patsientide terveid ja  immunoloogiliste ning geneetiliste 
tegurite suhtes uuritud õdesid-vendi haiguse tekke suhtes kolm aastat.
4. Kõrvutada Eesti andmeid teistes riikides saadutega.
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Materjal ja meetodid
1. Uuritavad
Lapseeas alanud ISST-ga patsiendid
j  rühm— 29 Eestis 1993.-1994. aastal järjestikuliselt esmasavastatud pat­
sienti vanuses kuni 15 aastat, 18 poeglast ja  11 tütarlast. Sellelt rühmalt võeti 
veri antikehade määramiseks esimese nädala jooksul pärast diagnoosimist.
2. rühm— 97 lapseeas alanud ISST-ga patsienti, kes võeti Eesti laste ISST 
suhkurtõve registrist. Kahesajale registris olevale lapsele saadeti 1990. aastal 
kutse uuringus osalemiseks, millega 97 soostus. Nendelt võeti veri HLA-DR-ja 
HLA-DQ-alleelide levimuse määramiseks.
Lapseeas alanud ISST-ga patsientide terved õed-vennad
Lapseeas alanud ISST-ga patsientide 71 tervet õde-venda, kellel uuriti nii 
antikehade kui ka HLA-DR-ja HLA-DQ-alleelide levimust. Eesti ISST-ga laste 
registrist võeti saja lapse aadressid ja  perekonnale saadeti 1994. aastal kutse, 
kus paluti terveid õdesid ja  vendi osaleda uuringus. Neljakümne neljalt pere­
konnalt saadi nõusolek.
Kontrollgrupp
1. rühm
614 lasteaia- ja  koolilast vanuses 3-18 aastat kuuest Eesti piirkonnast (Tallinn, 
Tartu, Paide, Põlva, Nõo ja Jõgeva), keda uuriti Langerhansi saarekeste ja 
glutamaadi dekarboksülaasi vastaste antikehade suhtes. 1991. aastal kogutud 
kontrollgrupp jaotus viide vanuserühma: 3-5 aastat (118), 6-8 aastat (131), 
9-11 aastat (119), 12-14(124), 15-18 aastat (122).
2. rühm
103 Tartu Ülikooli arstiteaduskonna 1993. aasta esimese kursuse üliõpilast ja 
166 järjestikust doonorit Maarjamõisa Polikliiniku verekeskusest, kellel uuriti 
HLA-DQ-ja HLA-DR-alleelide levimust.
2. Meetodid
ICA määrati immunofluorestsentsmeetodil, GADA kvantitatiivse immuno- 
pretsipitatsiooni radioligandsel meetodil. LA-2A leiti radioimmunoloogilisel 
meetodil. HLA-DR- ja  HLA-DQ-alleele määrati originaalmeetodil M. Sjöroosi 
järgi (simultaneus triple-label hybridization assay fo r  HLA alleles). HLA-allee- 
le määrati kahes etapis. Esmalt uuriti DQB 1*0201, *0301, *0302, *0602/0603
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suhtes. DQB 1*0201-positiivsetel määrati ka DQA1*0201 ja *0501. Neid, kel 
esines DQB 1*0302, uuriti DRB 1*0401, *0402, *0403, *0404, *0405, *0408. 
DQB 1*0301-ja  *0302-positiivseid indiviide testiti DQB1*0304 suhtes.
Alleelide ja  antikehade levimuse erinevust hinnati %2~ ja Fisheri testiga. 
Normaalse jaotumusega muutujate kirjeldamisel kasutati keskmist ja  standard- 
hälvet. Korrelatsioonanalüüs teostati Spearmani meetodil. Statistiliselt oluliseks 
peeti p<0,05. Iga uuritud alleeli jaoks leiti šansside suhe (SS). Vajadusel 
kasutati Haldane’i korrektsiooni. Multiiplite võrdluste korral kasutati p väärtuse 
korrektsiooni Bonferoni järgi.
Tülemused ja arutelu
Lapseeas alanud vastavastatud ISST haigetel oli kõige sagedasem antikeha ICA 
(79%). Järgnesid GADA 38%-l ja  IA-2A 35%-l juhtudest. Vähemalt üks 
uuritud antikehadest leiti 86%-l vastavastatud ISST haigetest, kõik kolm 
uuritud antikeha ainult 17%-1.
ISST patsientide tervetel õdedel-vendadel leiti üks või rohkem uuritud 
antikeha 13-1 (18,4%). Kõige sagedamini leitud antikeha oli GADA — 17%-1. 
Järgnesid ICA 7%-ga ja IA-2A 5,6%-ga. Enamusel sellest rühmast — 
81,6%-1 — ei leitud ühtegi antikeha.
Tervete lasteaia- ja  koolilaste seas leiti ICA 10-1 (1,6%) ja GADA 14-1 
(2,3%). Kaks ICA- ja GADA-positiivset indiviidi haigestus edaspidi ISST-sse. 
Samu antikehi uuriti 1994. aastal korduvalt nendel 8-1, kel 1991. aastal leiti see­
rumis ICA ning kes polnud haigestunud ISST-sse. Selgus, et pooltel neist oli 
ICA kadunud, GADA tiiter aga vähenenud.
ISST haigetel leidus meie uuritud alleelidest kõige sagedamini 
HLA-DQB 1*0302 — 66%-l. Järgnes HLA-DQB 1*0201 (55%). Mõlemad 
alleelid esinesid ISST haigetel statistiliselt oluliselt sagedamini kui kontroll­
rühmas. Meie poolt uuritud HLA-DQB 1 alleelidest kandis kõrgeimat ISST riski 
*0302 (SS 8,9), mis ületas HLA-DQB 1 *0304 poolt edastatava haigestumisriski 
(SS 7,3). Viimatinimetatud alleeli oli ISST haigetel harva — 5%-l juhtudest. 
Statistiliselt oluliselt kõrgema ISST riskiga oli seotud ka HLA-DQB 1*0201, SS 
2,7 (p<0,05).
Madalaima ISST riskiga alleel Eestis oli HLA-DQB 1*0602/0603. See alleel 
oli 44%-l kontrollrühmast ja  ainult 2%-l ISST haigetest. DQB 1 *0602/0603 
vähendas ISST riski 38 korda, võrreldes nendega, kellel seda alleeli polnud. 
Samuti oli madala ISST riskiga DQB 1*0301, SS 0,2 (p<0,05).
Kõige sagedasem ISST haigetel esinev meie uuritud kahe alleeli kombi­
natsioon oli HLA-DQB 1*0201-DQA 1*0501, mis leiti pooltel. Tervete kontroll­
rühmas esines seda kombinatsiooni ka märkimisväärselt — 22%-l. ISST haigete 
hulgas oli sageduselt järgmine HLA-DQB 1*0302-DRB 1*0401, mida leiti
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43%-l uuritutest, kontrollrühmas aga oluliselt harvemini — 5,2%-l. Nende kahe 
alleelikombinatsiooniga kaasnenud ISST risk oli vastavalt 3,6 ja  13,9. 
DQB 1*0304-DRB 1*0408 oli ISST rühmas 5%-l ja  üldpopulatsioonis ainult
0,7%-l, SS 7,3 (p<0,05).
71-st õdede-vendade rühma liikmest haigestus kolmeaastase jälgimise 
käigus ISST-sse kolm (4%). Neist kahel oli HLA-DQB 1*0201-DQA 1*0501 
alleelide kombinatsioon, Eesti ISST haigete sagedasim, ja  ühel 
HLA-DQB 1*0302-DRB 1*0401. Kõik kolm haigestunud lähisugulast kuulusid 
nende 13 hulka, kellel leiti antikehad. Kõigil kolmel oli leitud vähemalt kahte 
liiki antikehi, ühel isegi kõiki uuritud kolme. Neil kõigil kolmel olid antikehad 
GADA vastu.
Käesolev uurimus kirjeldab ISST-ga seotud antikehade ICA, GADA ja 
IA-2A levimust Eestis vastavastatud ISST-ga laste, ISST-ga laste tervete õdede- 
vendade hulgas ja  noorte kontrollrühmas. Kõige kõrgem kolme antikeha 
levimus oli ootuspäraselt vastavastatud ISST-ga laste seas, mis kinnitab 
aktiivselt käigus olevat autoimmuunset protsessi. Antikehade levimusmääralt 
järgnes õdede-vendade grupp, kelle seas omakorda oli antikehade sagedus 
kõrgem kui kontrollrühmas. ISST haigete esimese astme sugulaste suurem risk 
haigestuda ISST-sse võrreldes üldpopulatsiooniga leidis kinnitust: 4% nendest 
haigestus kolme jälgitud aasta jooksul.
On leitud, et ICA levimus populatsioonides on umbes kümme korda kõrgem 
ISST levimusest, s.t. enamusel ICA-positiivsetest isikutest ei arene kunagi 
haigust. Üldpopulatsiooni ICA levimuse kõrvutamisel meie omaga samaselt 
tehtud uurimustega Soomes, Prantsusmaal, Rootsis, Sardiinias ja  Rootsis selgus 
seos ISST haigestumuse ja  sama üldpopulatsiooni ICA levimuse vahel. Nendes 
populatsioonides, kus haigestumus ISST-sse oli kõrgem, oli suurem ka ICA 
levimusmäär (r=0,97, p<0,05), mis viitab sellele, et ICA-positiivsetest lastest 
haigestub erinevates populatsioonides umbes sama osa.
Käesoleva uuringuga täienes teave mitmete HLA-regiooni alleelide levi­
muse kohta Eestis, nii kontrollrühmas kui ka ISST haigete seas. Eesti ISST 
haigete kõrge ja  madala riski alleelid ei erinenud teiste Euroopa populatsioo­
nide. ISST suhtes madala riskiga alleelideks on Eestis DQB 1*0301 ja 
DQB 1*0602/0603, samaselt mitmetele teistele populatsioonidele. Märkimis­
väärne on madala riski alleeli DQB 1*0602/0603 suur levimus Eestis, eriti aga 
temaga kaasnev väga madal riskimäär (neli korda madalam kui Soomes). See 
võib olla üheks põhjuseks, miks Eestis on haigestumus ISST-sse üle kolme 
korra väiksem kui Soomes.
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Järeldused
1. Kõige sagedasem ISST-ga seotud antikeha vastavastatud patsientidel oli 
ICA (79%), sellele järgnes GADA (38%) ja IA-2A (35%). ISST patsientide 
tervetel õdedel-vendadel leiti samu antikehi oluliselt harvemini, ent sageda­
mini kui kontrollrühmas.
2. ICA esinemissagedus üldpopulatsioonis on lähedases seoses ISST haigestu­
musega (r=0,97; p<0,05). Tervete ICA-positiivsete laste osa, kel tekib ISST, 
on eri maades samane.
3. Kõige sagedasem esinev HLA-DQB 1 alleel ISST patsientide seas oli HLA- 
DQB 1*0302 (66%), sellele järgnes HLA-DQB 1*0201 (55%). Mõlemad 
alleelid esinesid statistiliselt oluliselt sagedamini ISST patsientide seas, võr­
reldes kontrollgrupiga.
4. Kõige kõrgema ISST riskiga alleel oli HLA-DQB 1 *0302, mille SS oli 8,9, 
järgnes HLA-DQB 1*0304 (SS 7,3).
5. Kõige madalama ISST riskiga alleel Eestis oli HLA-DQB 1*0602/0603. See 
alleel esines kontrollgrupis 44%-l. Selle alleeliga kaasnev ISST risk on Ees­
tis ligikaudu neli korda väiksem kui Soomes. Antud tulemus võib osaliselt 
seletada üle kolmekordset ISST haigestumuse erinevust Eestis ja Soomes.
6. Kõige sagedasem alleelide kombinatsioon ISST patsientide seas oli HLA- 
DQB 1*0201-DQA 1*0501, mis esines pooltel, järgnes HLA-DQB 1 *0302- 
DRB 1*0401 (43%). See tulemus on kooskõlas teiste valge rassi seas läbi 
viidud uuringutega.
7. ISST patsientide tervetel õdedel-vendadel oli suurem risk haigestuda ISST- 
sse võrreldes üldpopulatsiooniga. 4% ISST haigete õdedest-vendadest hai­
gestus kolmeaastase jälgimise vältel. Jälgimise algul leiti neil vähemalt 
kahte liiki antikehad ja neil olid Eestis kõige sagedamini ISST põdejatel 
esinevad HLA-alleelide kombinatsioonid.
16 61
ACKNOWLEDGEMENTS
I thank professor Toomas Podar for supervision, support and encouragement 
during the years.
I thank professor Vello Salupere, Head of the Department of Internal Medicine, 
University of Tartu, for important support and useful criticism.
I am indebted to my collaborators from the Hospital of Endocrinology, 
Clinicum of the University of Tartu, especially to Andrei Solntsev.
My special thanks go to B. Boehm, W. Richter, M. Knip, H.K. Âkerblom, 
J. Ilonen, E. Sabbah, P. Kulmala. Parts of the research were performed at the 
University of Ulm, University of Oulu and University of Turku.
Constructive comments were given by professors Raivo Uibo and Andres 
Metspalu.
Large help was provided by dr. Riina Shor from the Tallinn Central Children’s 
Policlinic in collecting blood samples.
I acknowledge the financial support from the Estonian Science Foundation, 
grant 1836. This research was also supported by Deutsche Forschungsgemein­
schaft, Finnish Academy and Foundation for Pediatric Research in Finland.
My gratitude also goes to my family for their ever-present support.
62
PUBLICATIONS

Adojaan В, Knip M, Vähäsalo P, Karjalainen J, Kalits I, Àkerblom HK.
Relationship between the incidence of childhood IDDM and 
the frequency of ICA positivity in nondiabetic children in the general population.
Diabetes Care 1996; 19: 1452-1454.
Relationship 
B ttw M n Нм 
Incidence eff 
Childheed IDDM and 
Hie Frequency eff ICA 
Positivity In 
Nondiabetic Children 
in the General 
Population
There is a considerable difference in the incidence of IDDM among chil­dren in ihe iwo neighboring coun- 
m es Finland and Estonia with an approxi­
mately three limes lower rate in Estonia 
(1). On the other hand, there are marked 
ethnic similarities between Estonians and 
Finns, suggesting that environmental fac­
tors may make a crucial contribution to 
the observed difference in incidence. 
Cytoplasmic islet cell antibodies (ICAs) 
are considered to be secondary markers of 
ongoing ß-cell damage, which eventually 
leads to the clinical manifestation of IDDM 
in some individuals once a majority of the 
ß-cells have been destroyed (2). Assess­
ments of the frequency of ICA positively 
among nondiabetic children have shown 
clear geographic variation (3 -5 ) and have 
resulted in speculations regarding a possi­
ble relationship between the prevalence of 
ICAs in the background population and 
the incidence of the disease. The highest
ICA frequency, 4.1%, has been observed 
in nondiabetic Finnish children (3). To 
test the hypothesis that the incidence of 
childhood IDDM is related to the fre­
quency of ICA positivity in nondiabetic 
children, we decided to study the latter 
among nondiabetic Estonian children and 
compare it with that found in Finland.
The study populations included 614 
healthy Estonian children and adolescents 
with a mean age of 10.6 ± 4.3 years (range, 
2.6-17 .9  years) and 1,212 Finnish subjects 
with a mean age of 10.7 ±5.1 years (range, 
3 -18  years). The Finnish popuiaiion has 
been described in detail previously (3). 
The Estonian population included 314 
boys (50.9%). The subjects represented 
five age-groups (3-5 , 6- 8 , 9 -11 , 12-14, 
and 15-17 years) and came from six 
regions of Estonia. Blood samples were 
obtained by venipuncture, and the serum 
samples were stored at -2 0 °C  until ana­
lyzed. ICAs were determined in the 
Research Laboratory of the Depanment of 
Pediatrics at the University of Oulu, Oulu, 
Finland, by a standard immunofluores­
cence method from sections of a frozen 
human group-O pancreas (6). Fluorescein- 
conjugated rabbit anti-human IgG 
(Behringwerke, Marburg, Germany) was 
used to detect ICAs. All the Finnish sam­
ples were screened with the same substrate 
in 1987-1988, and the Estonian samples 
were analyzed in 1991 using another sub­
strate that gave a standard curve similar to 
that obtained with the first one using an 
international reference standard that was 
derived from the Stage IV ICA Standardiza­
tion Workshop (7). Endpoint dilution 
liters for all positive Estonian and Finnish 
samples were examined using the same 
substrate and the results expressed in Juve­
nile Diabetes Foundation units (JDF щ  
relative to the above-mentioned interna­
tional reference standard. The detection 
limit was 2.5 JDF U. Our laboratory has 
participated in the International Work­
shops on the Standardization of Cytoplas­
mic ICAs, in which its sensitivity was 
100%, specificity 98%, validity 98%, and 
consistency 98% in the fourth round.
Other countries were selected for the 
comparison between die frequency of ICA 
positivity in the nondiabetic child popula­
tion and the incidence of childhood IDDM 
on the following criteria: I) reliable inci­
dence data available from a ume that was 
close to or the same as the penod during 
which the serum samples for the ICA 
assay were collected and 2) ICA assays that
1452 D iabetes  C a r e , v o l u m e  1 9 , n u m b e r  1 2 , D ecem ber  1996
Letters
Figure  1— Correlation between the annual incidence of childhood IDDM and the prevalence of ICAs 
in nondiabetic children in six countries. The error bars represent 05% Ch. The ICA frequency data are 
based on the present study and those of Levy-Marchal et al (4). Landin-Olsson et al. (5), Bingley et al 
(8), and Muntoni et al (9), while the incidence data were derived from Tuomilehto et al. (1), Green et 
al. (10), and Nystrôm et al. (1I).
were carried out in a laboratory participat­
ing in the International Workshops on the 
Standardization of Cytoplasmic ICAs and 
having reliable performance characteris­
tics. The results were evaluated statistically 
using cross-tabulation and x2 statistics or 
the Fisher's exact probability test, the 
Mann-Whitney U test for the comparison 
of the ICA levels between two groups, and 
linear regression analysis.
Ten Estonian children (1.63%; 95% 
Cl 0 .63 -2 .63 ) tested positive for ICAs, 
compared with 50 Finnish children 
(4.13%, 95% Cl 3 .01-5.25; P <  0.01), 
and 6 children from Estonia (0 98%, 95% 
Cl 0 .2 0 -1 .7 6 )  and 23 from Finland 
(1.90%, 95% Cl 1.13-2.67; 0.05 <  P <
0.1) had an ICA level of S 2 0  JDF Ü. Four 
Estonian boys (1.27%, 95% Cl 0 .03-2 .51) 
and 27 Finnish boys (4.80%, 95% Cl 
3.04-6.57; P <  0.05) were observed to be 
ICA*, whereas there was no significant 
difference in the frequency of ICAs 
between Estonian (6 of 300; 2.00%, 95% 
Cl 0 .42 -3 .58 ) and Finnish girls (23 of 
649; 3.54%, 95% Cl 2 .12-4 .96). The lev­
els of ICAs in the positive Estonian sub­
jects (median, 34 JDF U; range, 3 -97  JDF 
U) were similar to those in their Finnish 
counterparts (median, 16 JDF U; range, 
3 -1 2 8  JDF U, P = 0.28). Comparison of 
the frequency of ICA positivity in nondia­
betic children with the incidence of child­
hood IDDM in six countries showed a 
highly significant correlation (Fig. 1), indi­
cating that 94% of the variation in disease 
incidence between countries could be 
explained by the frequency of ICA posiliv- 
ity in the nondiabetic child population.
The present study shows that the fre­
quency of ICA positivity in nondiabetic 
Estonian children is about one third of that 
in nondiabetic Finnish children, a ratio 
which is of the same magnitude as that 
observed in the incidence of IDDM. There 
seems to be a close correlation between the 
incidence of the disease and the prevalence 
of ICAs in nondiabetic children in various 
countries, which suggests that a similar 
proponion of ICA+ children will eventu­
ally present with IDDM in all countries 
Since close to 0.6% of Finnish children will 
contract IDDM before the age of 20 (A. 
Reunanen, unpublished observations), the 
frequency of ICA positivity is almost seven 
times higher than the cumulative incidence 
of the disease. In addition, 10-20% of sub­
jects with IDDM test negative for ICAs at 
diagnosis. Taken together, this implies that 
a maximum one out of eight nondiabetic
1CA+ children will eventually present with 
the disease. What will happen to the 
remaining seven? One or two of them may 
present with IDDM later in life, but a 
majority of them will remain unaffected In 
the previous study of the Finnish popula­
tion, four out of 39 initially 1CA+ children 
(10.3%) became negative over an observa­
tion period of 6 years (3), suggesting that 
the immune attack against the ß-cells may 
be turned off in a portion of the subjects.
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The rare HLA-DQB 1 *0304 allele was found increased among IDDM patients 
in the populations of the eastern Baltic region. Its frequency among IDDM 
patients was 4.5% (20/443) compared to 1.1% (9/853) in healthy controls in 
the combined series of Estonian, Latvian and St. Petersburg Russian popula­
tions (P=0.000I). HLA-DQB 1 *0304 in these populations was associated with 
DRB 1*0408, and the haplotype was further characterized by a B35 allele and 
a typical combination of microsatellite markers from the TNF gene region. 
The result is compatible with the significance of the 57th amino acid in the 
DQ ß-chain but also emphasizes the importance of alleles in other HLA loci 
adjacent to DQ in the determination of IDDM susceptibility.
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HLA-DQB 1 *0304 is a rare DQB 1 *03 subtype com­
bining features of both DQB 1*0301 and 
DQB 1*0302 alleles within the hypervariable region 
of the second exon of DQB1 gene (1,2). Similar to 
DQB 1*0302 the amino acid 57 of the ß-chain of 
DQB 1 *0304 is a non-Asp amino acid (alanine) sug­
gested to be crucial in susceptibility to insulin-de­
pendent diabetes mellitus (IDDM), whereas other 
polymorphic amino acids are identical with the 
DQB 1*0301 allele associated with protection 
against IDDM (3).
The occurrence of this allele in the region of the 
eastern Baltic became evident during the valida­
tion of a rapid screening method for genetic 
IDDM susceptibility. The method is based on de­
tection of DQB1 alleles significantly associated
532
with susceptibility to (*0302 and *02) or protec­
tion against IDDM (*0602/*0603 and *0301) (4). 
The sequence-specific oligonucleotide probes hy­
bridizing with *0301 and *0302 were from regions 
encoding the amino acids 43-47 and 54-58, re­
spectively, and the presence of *0304 would thus 
produce a positive reaction with both probes. The 
samples giving three positive reactions including 
*0301 and *0302 together with *02 or *06027 
*0603 were rare during the validation of the 
method in Finnish IDDM and control subjects (5) 
but were more common when we analyzed the fre­
quency of susceptible and protective DQ alleles in 
neighboring Baltic regions. This encouraged us to 
conduct a systematic study of the frequency of 
DQB 1*0304 in these populations.
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Table 1.
The frequency of DQB1 *0304 in studied populations. OR = odds ratio
Population IDDM patients Controls P* OR
Estonians 5/97 (5.1%) 2/269 (0.7% ) 0.022 7.3
Latvians 6/136 (4.4%) 2/18 2 (1 .1% ) NS 4.2
Russians 9/210 (4.3%) 5/402 (1.2% ) 0.035 3 6
Total 20/443 (4.5%) 9/853 (1 1%) 0.0001 4.4
Finns 0/11 7(0% ) 1/200 (0.5% ) NS 0.6
aP value was calculated using chi-square test with continuity correction,
All samples which were found positive for both 
*0301 and *0302 in the screening test were reana­
lyzed for the presence of the DQB 1*0304 allele us­
ing sequence specific primers described by Olerup 
et al. (6). The results of DQB 1*0304 typing in vari­
ous population samples are shown in Table 1. Al­
though being a rare allele, DQB 1*0304 was actually 
increased among IDDM patients from St. Peters­
burg, Estonia and Latvia, and the difference be­
tween diabetic patients and controls was highly sig­
nificant in the combined series (Table 1). The pa­
tients were all diagnosed to have IDDM before the 
age of 15 years and control subjects were healthy 
blood donors. Ethnic Estonians and Latvians were 
selected for the study from these two countries with 
sizeable Russian minorities. In a further series of 
117 IDDM patients and 200 healthy controls from 
northern Finland only one DQB 1*0304 positive 
sample was found in the control group. In eight pos­
itive samples the polymorphic segment of the HLA- 
DQB 1 second exon was specifically amplified using 
*0301/*0304 specific primers and sequenced by an 
automated sequencer (PE Applied Biosystems, Nor­
walk, CT, USA). In all cases the *0304 specific se­
quence was confirmed.
The haplotypic combinations of DQB 1*0304 
were further studied by performing DR4 subtyping 
using a combination of subgroup-specific amplifica­
tion (7) and subsequent hybridization with digoxi- 
genin-labeled sequence-specific oligonucleotide 
probes (8). This demonstrated the presence of the 
DRB 1*0408 allele in all 20 DQB 1 *0304-positive 
patients with IDDM and in all but one of the 
healthy controls (8/9). Sequencing of the amplified 
DRB1 gene segment in two cases confirmed the 
presence of the DRB 1*0408 specific nucleotide se­
quence. When HLA-B alleles known to be in link­
age with DR4 were studied using sequence-specific 
amplification (9) in Estonian and Russian samples, 
HLA-B35 (B3501-3508, 5301) was found in 10 of 
14 patients with IDDM (71%) and in all six control 
samples (100%) positive for DQB 1*0304- 
DRB 1*0408, whereas it was present in only 49 of
325 (15%) of DQB 1 *0302-DRB 1 *04-positive 
samples (P < 0.0001, Pc < 0.0001). Further analysis 
of TNF gene region microsatellite markers (10) us­
ing fluorescence labelled primers to amplify and au­
tomated sequencer to measure the size of amplified 
microsatellites revealed the 10-4-1 allele combina­
tion of TNF a-b-c markers in all but one of the 15 
studied samples with DQB 1*0304-DRB 1*0408- 
B35 compared to a frequency of five in another 49 
(10%) analyzed samples with various DQB1*0302- 
DRB1 *04 combinations (PcO.OOOl, Pc<0.0001). 
The TNF 10-4-1 combination was also present in 
one IDDM patient positive for DQB 1*0304- 
DRB1 *0408 but negative for B35 allele.
We have accordingly demonstrated the occur­
rence of a new “extended” haplotype in the eastern 
Baltic region combining distinctive features within 
the class I and TNF gene region together with 
DRB 1*0408-DQB 1*0304 in the class II region. In 
the report of six samples positive for DQB 1 *0304 in 
North America, half of them were associated with 
DRB 1 *0403 and half with DRB 1 *0408 ( 1 ). The lat­
ter one was detected also in three DQB 1 *0304 posi­
tive Czech gypsies (11) similarly to the observation 
in the present study whereas the Sardinian haplo­
type combines DQB 1*0304 with DRB 1*0403 (12). 
The geographic distribution of the DQB 1*0304- 
DQB 1*0408 haplotype remains to be defined by 
further studies, but this haplotype may apparently 
serve as a marker in anthropological and disease as­
sociation studies.
Although detected in only 4—5% of patients with 
IDDM from this region its definitive association 
with disease susceptibility provides some insight 
into the determination of genetic IDDM risk. The 
Sardinian haplotype linked the DRB 1*0403 allele 
with DQB 1*0304, and the association of this par­
ticular haplotype with decreased IDDM risk is in 
line with the hypothesis that the combined effect 
of DR and DQ molecules plays a crucial role in de­
termining genetic susceptibility to IDDM (13). It 
has been observed in several studies that 
DQB 1*0302 is not a risk marker when found to­
gether with the DRB 1*0403 allele or the very simi­
lar DRB 1*0406 common in Oriental populations 
(13-16). Our data on DRB 1*0408-DQB 1*0304 
are compatible with this idea as well as the hypoth­
esis on the importance of amino acid 57 in the DQ 
ß-chain. The change at this position from aspartic 
acid to alanine is enough to convert protection into 
susceptibility, if this effect is not blocked by the 
presence of DRB 1*0403. However, even the 
DRB 1*0408-DQB 1*0302 haplotypes have been 
found to be strongly decreased among Mexican- 
American subjects with IDDM (17). An alternative 
explanation might be that the effect of DRB alleles
533
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in modifying IDDM susceptibility associated with 
the DQ molecule in fact reflects the impact of 
more distant, so far, uncharacterized genes in hap- 
lotypic linkage.
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The Effect of HLA-B Allele on the IDDM Risk 
Defined by DRB1*04 Subtypes and DQB1*0302
S ergei N e je n ts e v , H e le n a  R e ijo n e n , B e la  A d o ja a n , L iliy a  K o v a lch u k , A r th u r  S o c h n e v s , E u g e n e  I. S ch w a r tz  
Hans K. A k e rb lo m , a n d  J o r m a  H o n en
The g en es  e n c o d in g  th e  HLA -D Q  h e te r o d im e r  m o le ­
cules, DQB1 an d  D Q A 1, h a v e  b e e n  fo u n d  to  h a v e  th e  
stron gest a s s o c ia t io n  w ith  IDD M  r isk , a lth o u g h  th e r e  
is cu m u lative e v id e n c e  fo r  th e  e f f e c t  o f  o th e r  g e n e  lo c i  
w ithin  th e  m ajor h is t o c o m p a t ib i l i t y  c o m p le x  g e n e  
region. A fter  th e  HLA-DQ lo c u s , th e  HLA-DR lo c u s  h as  
been su g g e ste d  m o st  o f t e n  a s  c o n tr ib u t in g  to  th e  d is ­
ease su sce p tib ility . In  t h is  s tu d y  w e  a n a ly z e d  a t  th e  
population  le v e l th e  e f f e c t  o f  D R 4 s u b ty p e s  an d  c la ss
I, HLA-B a l le le s ,  on  IDD M  r isk  w h en  th e  in f lu e n c e  o f  
the DQ lo c u s  w a s s tr a t if ie d . In  a ll th r e e  p o p u la t io n s  
studied (E s to n ia n , L a tv ian , an d  R u s s ia n ) , D Q B 1*0302  
h aplotypes m o s t  fr e q u e n t ly  c a r r ie d  D R B 1 * 0 4 0 1  or  
DRB1*0404, D R B 1*0401  w a s th e  m o st  p r e v a le n t  s u b ­
type in  IDDM p a t ie n t s ,  w h e r e a s  D RB 1 * 0 4 0 4  w a s  
decreased in freq u en cy . DRB 1*0402  w a s a ls o  p r e v a le n t  
among R u ssian  h a p lo ty p e s , b u t  w a s  n o t  a s s o c ia t e d  
with IDDM r isk . W hen HLA-B a l le le s  w e r e  a n a ly z e d , 
strong a s so c ia t io n s  b e tw e e n  th e  p r e s e n c e  o f  s p e c if ic  В 
a lle les and D R B 1*04  s u b ty p e s  w e r e  d e t e c t e d . T h e  
HLA-B39 a lle le  w as fo u n d  s ig n if ic a n t ly  m o re  o f te n  in  
D R B l* 0 4 0 4 -D Q B l* 0 3 0 2 -p o s it iv e  p a t ie n t s  th a n  in  
healthy c o n tro l s u b je c ts  p o s i t iv e  fo r  th is  h a p lo ty p e :  
27 o f  54 (50% ) v s . 4  o f  49  (8 .2 % ) ( P  < 0 .0 0 0 1 ) .  T h e  
resu lts d e m o n str a te  t h a t  DQ an d  DR g e n e s  c a n n o t  
explain a ll o f  th e  H L A -link ed  s u s c e p t ib i l i ty  to  IDD M , 
and th at th e  e x is te n c e  o f  a  s u s c e p t ib i l i ty  lo c u s  te lo m -  
eric to  DR is  p ro b a b le . D ia b e te s  4 6 :1 8 8 8 -1 8 9 2 , 1997
The gen etic  com p on en t in the su sceptib ility  to  IDDM is w ell recognized, as is the localization  o f  the nuyor susceptib ility  loc i w ithin the HLA gene  region (1). R ecent genom e-w ide studies have con­firmed the importance o f  HLA but have also brought evidence 
for more than 10 other chrom osom al loc i affecting d isease  
risk (2). The genes coding for HLA-DQ heterodim er m olecules  
have been found to be m ost strongly associa ted  w ith IDDM 
susceptibility or protection against it, suggesting a direct role 
of these m olecules in d isease  p athogenesis (3).
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PCR, polymerase chain reaction
IDDM risk can be defined by th e presen ce o f  particular DQ 
alleles. In m o st o f  th e N orth E uropean  popu lation s, 
D Q B1*0302, w hich  is k now n  to  carry the stron gest su scep ti­
bility to  IDDM, is highly prevalent, w h ereas DQB 1*0201 is 
m ore prevalent in South European populations. DQB1*0602, 
*0603, and *0301 have b een  sh ow n  to  b e protective a lle les in 
m ost p opu lation s (4). H ow ever, severa l stu d ies h ave su g ­
gested  participation  o f  o th er HLA gen e loc i in  IDDM p atho­
gen esis, although, b ecau se  o f  the strong linkage disequilib­
rium, it is d ifficult to  estim ate their separate role. The DRB1 
gen e is the m ain candidate for an additional susceptib ility  
locus, b eca u se  DQB1*0302 h aplotyp es w ith  d ifferent DR4 
sub typ es con fer  an unequal risk  for th e  d isease  (5).
To clarify th e  question  o f  susceptib ility  loc i in  addition  to  
DQ, w e  investigated DR4 subtypes in  patients and control sub­
jec ts  m atched for the DQB1*0302 allele in Russian, Estonian, 
and Latvian populations, w hich  so  far are poorly  defined  for 
DR4 subtypes. Further, w e  stud ied  the e ffec t o f  c la ss I HLA 
В gen e a lle les on  the IDDM risk defined b y com b in ation s o f  
specific  DRB1 sub typ es w ith  DQB1*0302
RESEARCH DESIGN AND METHODS
Subject«, individuals from three Baltic populations—Estonians. Latvians, and 
Russians from SL Petersburg—were studied. Ethnic Estonians and Latvians from 
these two countries with sizable Russian minorities were selected for the study. 
The IDDM patients were unrelated subjects; in the Estonian and Latvian popu­
lations, age at diagnosis of disease was <15 years; the S t Petersburg population 
included some young adults. The mean age (± SD) at diagnosis of Estonian 
patients was 7.4 ± 3.8; of Latvian patients, 8.2 ± 3.8; and of Russian patients, 11.4 
± 6.2 years. Female patients made up 54,51, and 60% of the Estonian. Latvian, and 
Russian patient populations, respectively. Control samples were obtained from 
healthy blood donors or university students. EDTA blood was collected, and 
DNA was extracted using a standard salting out method.
Study design. In the first phase, 210 IDDM and 402 control subjects from the Russ­
ian population, 97 IDDM and 269 control subjects from the Estonian population, 
and 136 IDDM and 182 control subjects from the Latvian population were stud­
ied for HLA-DQB1 markers associated with IDDM risk using a rapid screening 
method based on lanthanide-labeled probes and time-resolved fluorometry (6). 
All subjects positive for DQB 1 *0302 were selected for the further DR4 subtyping, 
which was carried out by genomic amplification in two polymerase chain reac­
tions (PCRs), with the primer sequences as defined by Olerup and Zettenjuist (7). 
The following primers were used:
5 04 5'-GTT TCT TGG AGC AGG TTA AAC A-3’,
3'047 5-CTG CAC TGT GAA GCT CTC AC-3', 
and 3'048 5'-CTG CAC TGT GAA GCT CTC CA-3 .
Primers were specific for DRB1*0401,*0405,*0407,*0408,*(M09 (5'0»-3'047) and 
•0402,*0403,*0404,*0406,*0410,»0411 (5'04-3'048). The alleles were further dis­
tinguished by dot blot hybridization of the amplification product using the fol­
lowing “P-or digoxygenin-labeled sequence specific oligonucleotides:
5 -GGT GTC CAC (TTC GGC CCG CC-3' DRB1*0403, *0406, *0407, *0411 
5'-GCA GAG GCG GGC CGC GGT-3’ DRB1*0404, *0405, *0408, *0410 
5 -CGG CCT AGC GCC GAG TAC-3' DRB1*0405. *0409. *0410, *0411 
5 -GAA GAC GAG CGG GCC GCG-3' DRB1*0402 
5'-GAG CAG AAG CGG GCC GCG-.T DRB 1*0401, *0409
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TABLE 1
Frequencies (%) o f  HLA-DRB 1*04 subtypes in DQBl*0302-positive patients and control subjects
Estonians Latvians Russians Combined
IDDM Control IDDM Control IDDM Control IDDM Control
Allele (n  = 62) (n = 47) P (n  = 76) (n = 13) (n = 148) (n = 75) P (n  = 286) (n = 136) P
0401 72.6 26.5 <0.0001 60.5 38.5 57.4 37.3 0.007 61.5 33.3 <0.0001
0402 1.6 8.5 11.8 0 18.9 25.3 13.3 17.0
0403/6 0 6.4 0 0 0 1.3 0 3.0 0.017
0404 29.0 53.2 0.018 26.3 53.8 24.3 32.0 25.9 41.5 0.0018
040Б 3.2 2.1 0 0 2.7 1.3 2.1 1.5
0408 0 6.4 2.6 0 2.0 0 1.7 2.2
X* 0 4.3 6.6 7.7 2.0 6.7 2.8 5.9
•Nontypable.
The DR H 1*04 alleles were distinguished by combining results of specific 
amplification and riot Mot hybridization. DQB 1 *0302-positive samples were also 
analyzed (or the presence of nine HLA-B alleles (B*07, 62, 60, 36,66, 61, 27,30, 
and 44). These alleles were chosen for the study because they are known to be 
In linkage disequilibrium with DR4 in other Caucasian populations (8); or in par­
ticular, they are known to characterize IDDM-associated DR4 hapiotypes in the 
neighboring Finnish population (9,10). HLA-B typing was done by means of PCR 
with sequence-specific primers according to the method described by Bunco et
al-(11).
Statistical analysis. The level of significance was assessed by x* test in com­
parisons between different groups. Odd ratios were calculated according to the 
formula (a x it)/(6 x c), where a and 6 are the numbers of the IDDM patients that 
were positive and negative for the marker, respectively, and с and d, the respec­
tive numbers of control subjects.
RESULTS
The frequency o f  HLA D QB1*0302 w as highly increased  in 
IDDM p atien ts in  all p opulations, but DRB 1*04 subtyping  
revealed  an unequal risk o f  IDDM w hen  DQB 1*0302 w as  
found in con tex t o f  distinct DRB1-DQB1 hapiotypes (ТЫ>1е 1). 
D R B1*0401 w a s  a ssoc ia ted  w ith  IDDM in all populations, 
w hereas D QB1*0404 w as d ecreased  am ong IDDM patients, 
although th is e ffec t w as not significant am ong the R ussian  
patients. T h ese tw o  a lleles w ere the m ost prevalent subtypes  
in all three populations. Only in the R ussian patients w as  
DQB 1*0402 found  in a  con sid erab le  proportion  o f  
D Q B1*0302 h apiotypes, but w ith out any a ssoc ia tion  w ith  
IDDM. DQB 1*0403/6 a lle le s  w ere  n o t found in any o f  th e
patients, and although  a lso  rare in  con tro l sam ples, the 
d ecrease  am ong IDDM patients w a s sign ificant in the com ­
bined data.
HLA-B typing o f  se le c ted  a lleles w a s  perform ed only in 
Estonian and R ussian sub jects b ecau se  o f  the sm all number 
o f  Latvian control sub jects w ith  various DR4 subtypes. The 
analysis o f  all D Q B1*0302-p ositive su b jects w ith out taking 
DR4 sub typ es in to accoun t sh ow ed  an a ssoc ia tion  o f  B*39 
w ith  the d isease. B*7 and B*51 w ere  significantly d ecreased  
in the p atients in the com b in ed  ser ies  (Table 2).
A nalysis o f  В a lle les  a sso c ia ted  w ith  d ifferent DR4- 
D Q B1*0302 hapiotypes revealed ordinary allelic associations  
as w ell as som e d ifferen ces b etw een  IDDM and control sub­
jec ts  (Tables 3 -5 ). The B*62 a llele  w a s significantly more 
com m on  in DRB 1*0401 -DQB l* 0 3 0 2 -p o s itiv e  than in 
D R B1*0404-DQB1*0302-positive sub jects am ong both IDDM 
(P  = 0.002) and con trol su b jects (P  = 0.018). DRB1*0402- 
DQВ 1*0302. w hich  is prevalent in R ussian subjects, w as fre­
quently associa ted  with  B*51, and th is allele w as significantly 
m ore com m on  in DRB1*0402-DQB 1*0302-p o sitiv e  than in 
D R B l*0401-D Q B l*0302-p ositive p atien ts (P  = 0.0035).
The m ost con sp icu ou s d ifference b etw een  IDDM patients 
and control su b jects w as found am ong DRB 1*0404- 
D Q B l*0302-positive subjects. В*39 w as found in half o f  both  
Estonian and Russian IDDM patients, compared with only a few  
c a ses  am ong control subjects. The d ifference w as significant
TABLE 2
Frequencies (96) o f HLA-B alleles in HLA DQB 1*0302-positive IDDM patients and healthy control subjects
Allele
IDDM
(n = 58)
Estonians 
Control 
(n = 46) P
Russians 
IDDM Control 
(n = 146) (n  = 75)
IDDM 
(n  = 204)
Combined 
Control 
(n = 121) P
62 34.5 28.3 24.7 17.3 27.5 21.5
39 25.9 2.2 0.0023 14.4 6.7 17.6 5.0 0.0018
35 16.5 19.6 13.0 16.0 13.7 17.4
44 5.2 10.9 16.4 18.7 13.2 15.7
7 12.1 21.7 11.6 20.0 11.8 20.7 0.045
27 13.8 19.6 10.3 13.3 11.3 16.7
51 3.4 10.9 10.3 20.0 8.3 16.5 0 039
60 6.9 4.3 5.6 14.7 5.9 10.7
56 5.2 4.3 0.7 0 2.0 1.7
XX* 8.6 13.0 17.8 12.0 15.2 12.4
*None o f the above studied alleles. 
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TABLE 3
Frequencies  (%) o f HLA-B alleles  in HLA-DRB 1*0401-DQB l*0302-positive IDDM patien ts  and healthy contro l sub jec ts
Allele
Estonians 
IDDM Control 
(n = 44) (n  = 14)
IDDM
(n = 85)
Russians
Control
(n = 28) P
IDDM
(n = 129)
Combined
Control
(«  = 42) P
62 43.2 35.7 37.6 39.3 39.5 38.1
39 15.9 0 5.9 3.6 9.3 2.4
35 18.2 14.3 23.5 10.7 21.7 11.9
44 6.8 21.4 16.5 21.5 13.2 21.4
7 6.8 14.3 11.8 14.3 10.1 14.3
27 13.6 14.3 9.4 10.7 10.9 11.9
51 0 14.3 5.9 14.3 3.9 14.3 0.043
60 4.5 0 2.4 21.4 0.0028 3.1 14.3 0.021
56 6.7 7.1 1.2 0 3.1 2.4
XX* 9.1 14.3 14.1 10.7 12.4 11.9
♦None of the above studied alleles
in both populations, and highly significant in the com bined  
series at the level o f  P  < 0.0001, even after multiplication by the 
number o f tested HLA-B alleles (Table 4). Calculations o f  rel­
ative risk estim ates or odds ratios for DRB1*0404-DQB1*0302 
with and without B*39 allele dem onstrated that the com bina­
tion with B*39 is a marker associated  with a higher risk than 
the DRB1*0401-DQB1*0302 haplotype, w hereas w ithout B*39, 
this haplotype carried n o susceptibility (Table 6).
The decrease o f  B*51 am ong IDDM patients that w as  
observed w hen com paring all DQB1*0302-positive subjects  
was further found in th ose w ith  the DRB 1*0401-DQB1*0302 
haplotype (Table 3). B*60 w as decreased in Russian and com ­
bined IDDM patients with DRB1*0401-DQB1*0302, w hereas  
B*35 was decreased  in DRB 1*0402-DQB 1 *0302-p ositive  
Russian IDDM patients com pared with healthy subjects w ith  
this haplotype. On the other hand, the number o f  subjects with­
out any o f  the tested  В a lle les  w as in creased  am ong  
DRB1*0402-DQB1*0302 patients (Table 5).
The age at d iagnosis or proportion  o f  m ale to  fem ale  
patients did not differ betw een patients with various HLA-DR4 
subtypes. Neither w ere differences found w hen th ose with the 
combination o f  HLA-DQB 1*0404 and B*39 a llele  w ere com ­
pared with other patients (data n ot show n ).
DISCUSSION
The resu lts  d escrib ed  in  th is  s tu d y  confirm  the p resen ce  o f  
severa l g en e loc i w ith in  th e  HLA region  re sp on sib le  for  the  
su scep tib ility  to  IDDM. The risk  d efin ed  by the stro n g est  
know n  s in g le  risk a llele , D Q B1*0302, is  d ep en d en t on  th e  
DR4 sub typ e. A m ino acid  re sid u es  d iffering b etw een  DR4 
a lle le s  partic ipate in  th e  form ation  o f  th e  p ep tid e  b ind ing  
groove and have fu nction a l e ffe c ts  on  p ep tid e  b ind ing and  
antigen  p resen tation  (12). If th e  d isea se  su scep tib ility  and  
p rotection  a sso c ia ted  w ith  DQ m o le cu le s  is  m ed iated  by  
their role in  antigen  presen tation , th is  m ight in  fact be m ore  
precisely  defined by th e com bination  o f  different c la ss  П alle­
les, DQ and DR m o lecu les  together. H ow ever, so m e findings  
con trad ict th is  h yp oth esis . T he h ierarchy o f  D R4 a lle le s  in  
the defin ition  o f  su scep tib ility  th at h as b een  built in a cc o r ­
d ance w ith  severa l s tu d ie s  (6 ) is  n o t a  com m on  rule. In th e  
p resen t study, DRB 1*0402, w h ich  h as b een  found  in  so m e  
p opu lation s to  b e  th e stro n g est DR4 risk factor, d id n o t d if­
fer in freq u en cy  b etw een  R ussian  p atien ts and con tro l su b ­
je c ts . A lso , th e  p op u la tio n s w ith  th e  h igh est IDDM in c i­
d e n ce  (1 3 )— F inn s and S can d in av ian s— p ractica lly  lack  
th o se  D R4 su b ty p es  reported  to  b e  a sso c ia te d  w ith  th e  
h ig h est risk, 0402 and 0405  (1 4 -1 6 ) . T h e e ffe c t  o f
TABLE 4
Frequencies (%) o f HLA-B alleles in HLA-DRBl*0404-DQBl*0302-positive IDDM patients and healthy control subjects
Allele
Estonians Russians Combined
IDDM
(n =  17)
Control
(n = 25) P
IDDM
(n = 37)
Control
(n  = 24) P
IDDM
(n = 54)
Control
(n = 49)
62 11.7 28.0 16.2 0 14.8 14.3
39 52.9 4.0 0.001 48.6 12.5 0.0086 50.0 8.2
35 11.7 16.0 5.4 16.7 7.4 16.3
44 0 4.0 13.5 16.7 9.3 10.2
7 23.5 24.0 16.2 29.2 18.5 26.5
27 17.6 28.0 10.8 12.5 13.0 20.4
51 5.9 0 5.4 16.7 5.6 8.2
60 5.9 8.0 13.5 16.7 11.1 12.2
56 0 4.0 0 0 0 2.0
XX* 5.9 12.0 2.7 12.5 3.7 12.2
•None of the above studied alleles.
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TABLE 5
Frequencies (%) of HLA-B alleles in Russian HLA-DRB 1*0402- 
DQBl*0302-positive IDDM patients and healthy control subjects
Allele
IDDM
(n = 28)
Control 
(n  = 19) P
62 3.6 10.5
39 3.6 5.3
35 0 21.4 0.046
44 21.4 15.8
7 0 10.5
27 10.7 15.8
51 28.6 31.6
60 3.6 5.3
56 0 0
XX* 42.9 10.5 004
*None of the above studied alleles.
DRB 1*0404 varies in its  p ro tective  e ffec t in d ifferent p opu ­
lations, from  stron g  to  w eak  or  lacking (14 ,15,17,18), as in 
the p resen t report.
Our study a lso  suggested  a strong specific heterogeneity in 
the effec t o f  DRB1*0404-DQB1*0302 haplotype, depending on  
the p resen ce  or  ab sen ce o f  B*39 allele, w ith  a  strong d isp o­
s ition  being conferred in the form er and no disposition  b eing  
conferred in th e  latter. This resu lt m ight be attributable to  a 
haplotypic effec t, but th is cannot b e  confirm ed in a popula­
tion  study. In a  Finnish fam ily study, B39 divides DRB1*0404- 
D Q B1*0302 h aplotypes sim ilarly in term s o f  IDDM risk (19). 
In th e F innish population , B39 is a lso  strongly assoc ia ted  
w ith  A24, w ith  A 24 (9), B39 (16), DR4 being on e o f  the m ost 
com m on  DR4 h aplotypes found in IDDM patients (9,10,20). 
A24, B39, and DR4 h aplotypes have n o t b een  reported as 
su scep tib ility  h ap lo typ es e lsew h ere , but A24 h as b een  
recently found to be associated with an earlier age at diagnosis 
and w ith  a m ore rapid progression  to  IDDM in an Australian  
fam ily ser ies  (21). A  recent study from  S t  Petersburg also  
reported th e in crease o f  both  A24 and B16 a lle les am ong  
R ussian IDDM p atients (22).
O ther d ev ia tion s in В a lle le  freq u en cies b etw een  DR- 
D Q -m atched IDDM and control subjects found in the present 
study also  support the role o f  c la ss  I genes. The decreased  B7 
frequency am ong IDDM patients w as sh ow n  only w hen  all 
D Q B1*0302-positive subjects w ere com pared. T his decrease  
m ay b e secon d ary  to  th e  d ecrea se  o f  linked DRB1*15- 
DQB 1*0602 a lle les protecting  against IDDM, and m ay reflect 
the genotype e ffec t o f  the other chrom osom e. The d ecreased
frequency o f  B51 and B60, in stead , w a s  s een  on ly  in  
DRB 1*0401 -p o sitiv e  sub jects, and that o f  B35, only in 
D R B l*0402-positive subjects. H ow ever, th ese  associa tion s  
w ere detected  for the first tim e and w ere o f  low  statistical sig­
nificance, thus requiring further confirm ation.
The resu lts o f  the p resent study su ggest that cla ss  I a lleles  
have a separate role in  IDDM in addition  to DR and DQ. 
A nother possib ility  is that the a ssoc ia tion  o f  IDDM w ith cer­
tain DR4 subtypes appears to b e attributable to  the linkage dis­
equilibrium w ith  an unidentified gen e in th e HLA region. The 
h ypoth esis o f  an additional susceptib ility  locu s w ithin the 
m^jor h istocom patib ility  com p lex  region w as supported by 
recent m olecu lar findings (23,24), as w ell as by analogy with 
the NOD m ou se m od el (25). The role and localization  o f  
th ese  gen etic  e lem en ts  remain to  b e clarified.
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Distribution of insulin-dependent diabetes 
mellitus (IDDM)-ielated HLA alleles 
correlates with the différence in 
IDDM incidence in four populations 
of the Eastern Baltic region
Abstract: The high incidence of insulin-dependent diabetes mellitus 
(IDDM) in Finland contrasts strikingly with the low rates in the neighbouring 
populations of countries in the Eastern Baltic region: Estonia, Latvia and 
Russia. To evaluate the possible contribution of genetic factors to these dif 
ferences, the frequencies of HLA-DQB1 alleles and relevant DQB1-DQA1 or 
DQB1DRB1 hapiotypes associated with IDDM risk or protection were ana 
lysed among IDDM patients and control subjects from these four popula­
tions. An increased frequency of HLA DQBl *0302, DQB1*02-DQA1*05 and 
DQB1*0302-DRB1*0401 was observed in subjects with IDDM in all studied 
populations, whereas the prevalence of DQB1*0301 and DQB1*0602 and/or 
*0603 was decreased among patients. The degTee of IDDM risk associated 
with HLA alleles analysed here did not differ significantly between the popu­
lations. Comparisons of the distribution of IDDM-related HLA alleles and 
hapiotypes in the background populations revealed its consonance with 
IDDM incidence. The combined frequency of high risk genotypes was sig­
nificantly higher among Finns than in other populations studied. Our data 
support the hypothesis that variance in the dispersion of HLA alleles is the 
genetic basis of variation of IDDM incidence observed in the Eastern Baltic 
region.
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Insulin-dependent diabetes mellitus (IDDM) is common in popula­
tions of European ancestry, the highest incidence rates being ob­
served in Finland and Sardinia, the disease being rare among Asian 
Orientals (1, 2). Interestingly, major gradients in IDDM incidence 
are frequently found also between neighbouring populations which 
are considered as being genetically relatively close to each other. 
The Eastern Baltic region is a conspicuous example of a such re­
markable small-area variation. The incidence of IDDM is extremely 
high in Finland -  35.3 per 100,000 children under the age 15 annu­
ally (95% confidence interval (Cl): 33.1-37.5) -  whereas, in contrast, 
the incidenoe in the neighbouring Baltic countries and Russia is 
low: in Estonia 10.3 (8.9-11.7), in Latvia 6.5 (5.6-7.4) and in Russia 
5.6 (no data for 95% Cl available) (1). To clarify the reasons behind
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these differences is an intriguing challenge. Although we know that 
both environmental and genetic factors are involved in the patho­
genesis of IDDM, most of these factors remain poorly characterised. 
HLA genes are the best defined and, obviously, the major genetic com­
ponent in the disease aetiology (3). While the DQB1 and DQA1 genes 
are considered to be the primary IDDM genes, it is generally accepted 
that alleles of the DRB1 gene also affect the disease susceptibility (4).
In the present study we tested the hypothesis that differences in 
the distribution of IDDM-related HLA alleles could explain or, at 
least, would be in accordance with the observations of IDDM inci­
dence. To explore this issue we first studied whether the same al­
leles of the HLA DQB1 genes and relevant combinations of DQB1 
and DQA1 or DRB1 genes conferred the same degree of susceptibil­
ity or protection to IDDM in four neighbouring populations of the 
Eastern Baltic region. Subsequently, the distribution of IDDM-re- 
lated alleles and the proportion of individuals at high risk were 
compared between the background populations.
Patients and methods
Samples from patients with newly diagnosed IDDM were collected 
from the region of Oulu in Northern Finland and the region of Turku 
in Southwestern Finland. The patients had been diagnosed before the 
age of 16 at the Departments of Paediatrics, Oulu or Turku University 
Hospitals, after the year 1989, and had thus not been included in the 
earlier series of the "Childhood Diabetes in Finland" study. Reference 
samples were cord bloods of consecutive births at the same hospitals. 
The patients from Estonia and Latvia had also been diagnosed before 
the age of 16 but the series from St. Petersburg, Russia, included 
young adults. The patients and control subjects in Estonia and Latvia 
were ethnic Estonians and Latvians, respectively, since all subjects 
representing the sizeable Russian minorities in these countries were 
excluded from the study. Blood samples were collected from 97 Eston­
ian, 136 Latvian, 211 Russian and 316 Finnish (163 from Oulu and 
153 from Turku) IDDM patients and from 269 healthy Estonian, 173 
Latvian, 413 Russian and 1,000 Finnish (499 from Oulu and 501 from 
Turku) reference subjects.
The gene alleles defining the presence of the HLA-DQ hetero- 
dimer molecules known to be associated with IDDM risk or protec­
tion were determined using two steps. The samples were first 
studied for the presence of the DQBl*02,*0301,*0302 and *0602 or 
*0603 alleles using a method baaed on binding of the biotinylated 
amplification product onto streptavidin-coated microtitrc plate 
wells, followed by hybridisation with lanthanide-labelled oligonuc­
leotide probes. The fluorescence properties of the different lantha-
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nides (europium, samarium and terbium) allowed simultaneous de­
tection of three different reaction products in a single microtitre 
plate well with time-resolved fluorometry (5). The samples positive 
for DQB1*02 were further studied for DQA1*05 and *0201 alleles. 
This assay was based on a modified method in which biotinylated 
sequence-specific probes and a europium-labelled detection probe 
were utilised (6). The samples positive for DQBl *0302 were further 
studied for the presence of DR4 subtypes, i.e. alleles of the DRB1 
gene, known to be in linkage disequilibrium with DQBl *0302 and 
modifying the risk conferred by this allele (7). We used either a 
high-resolution technique of DR4 subtyping, which was designed 
according to the same principles as the assay for the DQBl gene 
(S. Nejentsev, M. Sjöroos, T. Soukka, M. Knip, O. Simell, T. Lövgren, 
J. Ilonen, manuscript in preparation) or conventional dot-blot hy­
bridisation (8). In the remaining cases the DQBl alleles alone were
regarded sufficient for the final analysis of the risk, as the amount 
of information increases minimally by the determination of the 
tightly linked DQAl and DRB1 alleles.
The chi-squared test with continuity correction was used for the 
analysis of statistical significance. Odds ratios (OR) were calculated 
according to the formula (axd)/(bxc), where a and b are the fre­
quencies of patients positive or negative for the given marker, re­
spectively, and с and d are the corresponding numbers for the con 
trol subjects.
Result« and discussion
HLA DQ allele associations which have consistently been found to 
be positively or inversely related to IDDM susceptibility in Caucasi-
IM fthn  risk (O K ) and * S %  confidence In te rva l« ( 9 5 %  C l)  conferred by DQ 8 1  a M a a  and of D Q B 1 -O Q A 1  and D Q B l -D f t B l  hapiotypes In th e  tour p eprtaH o i »  In th e  
Eastern Battle teflon
Finland Estonia Latvia Russia
OR 95% Cl OR 95% Cl OR 95% Cl OR 95% Cl
DQBl’0301 0.31 0.20-0.49 0.2 0.1-0.5 0.2 0.1-0.4 0.1 0.07-0.23
0061*0602-3 0.11 0.07-0.18 0.03 0.01-0.1 0.03 0.01-0.09 0.09 0.04-0 2
DOB1*02 2.7 2.1-3.6 2.7 1.6-4.4 3.6 2.2-6.0 3.7 26 -5.4
00ei*O2-DQAl*O5 2.9 2.2-3.9 3.6 2.1-6.0 4.3 2 .5 -75 4.7 3 0 - 6 6
0081*0302 10.0 7.4-13.5 8 9 5.1-15.6 15.4 8.0-30.0 9.7 6.5-14.5
DQB1*0302-DRB1*0401 8.4 6.4-11.4 14.7 7.2-39.9 17.7 6.5-52.7 8.5 5.2-13.8
DQBl*03020Rei*0404 3.6 2.4-5.4 2.3 1.1-4.7 4.6 1.8-12.2 2 Я 16 -4.9
Comportée« of froqaencloo (% ) of D Q B l  a M e t  and of D Q B l -D Q A l  end D Q B l -O f t B l  haptetypae I «  the four p o p i d t l oas In the  Easte rn  
Battle reflori
Allele or haplotype 
associated with Finland Estonia Latvia Russia
DQBl‘0301 protection 21.6* 33.5 39.9 39.0
DQB1*06023 protection 41.2 44.2 47.4 35.6“
DQB1-02 risk 25.5 31.2 29.5 28.1
DQB1*02-DQA1*05 risk 20.2 22.3 17.9 15 7*
DQBl’0302 mgn risk 19.3 17.8 9 2 “ 20.6
DQBl •0302-0R81 *0401 high risk 12.4* 5.8 2.9 7.5
OQB1*0302-DRB1*0404 risk 6.2 8.9 4.0 6.8
P IP eor=Px 4 2 ):
'  Wand n  Estonie<0 .0 0 0 0 ei < 0 .0 0 4 ). Finland vs U M e < 0 .0 0 0 0 0 1  (< 0 .0 0 0 0 5 1 . Finland vs Ru»*ia< 0  0 0 0 0 0 1  ( < 0  0 0 0 0 5 1
* «um* vs Finland- 0  0 5 7  (NS). Russia vs Estonia< 0  0 3  (NS). Russia vs LatviarO.Ol (NS)
* Russia vs Eatonia<0 .0 4  (NS). Russia vs Fmlend O Oe (NS)
* Latvia vs Fmiand<0 .0 0 0 2  (< 0 .0 0 9 ), Latvia vs Estonla<0 .0 2  (NS). Latvia vs Russla<0 .0 0 2  (NS)
‘ Finland vs Estonia<0 .0 0 3  (NSl.Fmiand vs latv>a<0 .0 0 0 4  (< 0 .0 2 ). Finland vs Ru*sla<0 .0 1 (NS)
Table 3
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ans were confirmed also here (Table 1). While no previous data on 
molecular typing of IDDM patients in Estonia or Latvia exist, in a 
recent study of patients with juvenile rheumatoid arthritis in Latvia 
the control population had very similar allele frequencies in the 
control population to those seen here. Typically, DQB1*0301 was 
found at high frequency and DQBl *0302 relatively seldom (9). The 
frequency of DQB1*0302 in the Latvian population is also in con­
cordance with earlier data on a low prevalence of the serologically 
defined DK4 antigen (10). Russian IDDM patients and controls from 
Moscow (11) showed similar frequencies of DQBl *0302, DQBl *0301 
and DQBl *0602 or *0603 alleles as the subjects from St. Petersburg 
in this study.
Results of DR4 subtyping in Finns and, as we have shown earlier 
(8), in Estonians, Latvians and Russians, revealed that DRB1*0401 
and *0404 were the only alleles found at significant frequencies and 
able to modify IDDM risk associated with the DQB1*0302 allele. In 
Russians *0402 was also present in a reasonable number of patients 
and controls but was a neutral marker in relation to IDDM risk. In 
Russian patients and controls matched for DQBl*0302, DRB1*0402 
was found in 18.5% and 22.4%, respectively, with an OR of 0.8 
(95% CI=0.4-1.6). The DRB1*0403, known to be a protective allele 
(12-14), was rare in all four studied populations and could not sig­
nificantly modify the risk conferred by DQBl *0302 (Table 1).
Although the relative risks of IDDM (OR) associated with DQBl 
alleles, DQB1-DQA1 and DQB1-DRB1 hapiotypes were not exactly 
the same between the populations studied, the 95% Cl were overlap­
ping in all comparisons (Table 2). This indicates that the same al­
leles and hapiotypes generally confer a similar degree of risk and 
the comparisons of their frequency in the background population 
will be valid in estimating the relative level of genetic susceptibility 
to IDDM in a particular population.
The comparisons of the frequency of HLA DQBl alleles, DQB1- 
DQA1 and DQB1-DRB1 hapiotypes between the four populations 
are shown in Table 3. Each population could be characterised in 
terms of the prevalence of IDDM-predisposing and IDDM-protective 
HLA alleles and/or hapiotypes. Finland was shown to have a de­
creased frequency (relative to other studied populations) of the pro­
tective DQBl *0301 allele and an increased frequency of the highly 
susceptible DQBl *0302-DRBl *0401 haplotype. In contrast, the 
Latvian population had a low prevalence of the highly susceptible 
DQB1*0302 allele and a tendency to an increased frequency of the 
protective DQB1*0301 allele. A population was considered to show 
a “tendency” of being different when the contrast in allele frequency 
was notable, but P-values became insignificant after correction for 
the number of comparisons done. Thus the Russian population 
could be characterised by the tendencies to an increased frequency 
of DQB1*0301 and a low prevalence of DQBl *0602-3, which both
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confer protection, and a tendency to carry the susceptible haplotype 
DQB1*02-DQA1*05 at a low frequency. In the Estonian population 
all protective and susceptible alleles and haplotypes were found to 
be distributed at intermediate frequencies. These data are mostly in 
accordance with the differences in the disease incidence observed 
between the populations studied.
Another approach for comparing the level of genetic susceptibil­
ity between populations is to compare the combined proportion of 
all individuals at risk. While representing a more direct estimate 
than the compansons of allele and haplotype frequencies, it is ham­
pered by the large number of genotypes, some of which being pres­
ent at very low population frequencies and often conferring different 
degrees of IDDM risk in various populations. In Table 4 we com­
pared combined population frequencies of all individuals at high 
risk, i.e. those carrying the DQB1*02/0302 or the DQBl*0302/x- 
DRBl*0401/v or the DQBl*02/v-DQAl*05/z genotype. The degree 
of risk conferred by each genotype was similar in the studied popu­
lations, as the 95% confidence intervals are overlapping in all com­
parisons When combined, these genotypes comprise 64.0% of all 
Latvian IDDM patients, 703% of Finnish, 72.2% of Estonian and 
68.7% of Russian IDDM patienta Although a substantial pro­
portion of individuals at low risk was not included in the analysis, 
the difference in the combined frequency of these genotypes in 
background populations was rather demonstrative: Finland has the 
highest proportion of susceptible individuals -  17.5%. Therefore, 
we can assume that, as far as HLA is the primary IDDM locus (3), 
the differences in the distribution of its alleles are the genetic basis 
of the variation of IDDM incidence. Our data support this hypo­
thesis.
In conclusion, we found that differences in the frequencies of 
IDDM-related, susceptible and protective HLA alleles and haplo­
types in the background population are in concordance with the 
variance in IDDM incidence observed in the Eastern Baltic re­
gion.
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Insuliini9Õltuv suhkurtõbi on sageli 
lapseeas algav raske krooniline haigus. 
Haiguse etioloogia ei ole siiani veel teada. 
Seetõttu puudub insuliinisõltuva suhkur­
tõve proflilaktika võimalus. Viimase 20 
aasta jooksul kogunenud andmed lubavad 
järeldada, et insuliinisõltuv suhkurtõbi 
tekib geneetiliselt vastuvõtlikel indiviidi­
del au to immuunse mehhanismiga (2,4). 
Paraku on immunoloogiliste ja geneetilis­
te tegurite seos insuliinisõltuva suhkurtõ­
vega komplitseeritud. Seetõttu on selle 
haiguse etioloogia ja patogeneeei pare­
maks mõistmiseks vaja uurida erineva ge­
neetilise ja keskkonna taustaga populat­
sioone (5,9). Praeguseks on informatsioon 
insuliinisõltuva suhkurtõvega seotud im­
munoloogiliste ja geneetiliste tegurite le­
viku kohta Eestis puudulik.
Eeltoodust lähtudes oli käesoleva 
uuringu peaeesmärgiks teha kindlaks 
mitme teadaoleva insuliinisõltuva suh­
kurtõvega seotud immunoloogilise ja ge­
neetilise teguri levik kolmes Eesti elanik­
konna rühmas: 1) vastavastatud lapseeas 
alanud insuliinisõltuva suhkurtõvega pat­
siendid; 2) lapseeas alanud insuliinisõltu­
va suhkurtõvega patsientide terved lähi­
sugulased ja 3) üldpopulatsiooni valim.
Eesmärgid: 1) leida uuringurühmades 
Langerhansi saarekeste vastaste (ICA),
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glutamaadi dekarboksü laasivastaste 
(GADA) ja türosiini foefataasi vastaste 
antikehade (IA-2A) levik; 2) teha kindlaks 
HLA-DQBI lookuse insuliinisõltuva suh­
kurtõve riskiga seotud alleelide ning mõ­
nede teiste HLA alleelide kombinatsiooni­
de esinemissagedus Eesti Qldpopulatsioo- 
nis ja insuliinisõltuvat suhkurtõbe 
põdejatel, samuti kaasnevad riskimäärad; 
3) jälgida insuliinisõltuvat suhkurtõbe põ­
dejate terveid õdesid-vendi haiguse tekke 
suhtes kolm aastat; 4) kõrvutada Eesti 
andmeid teistes riikides saadutega.
Uurimismaterjal ja -meetodid. Esi­
mese uuringurühma moodustasid lap­
seeas alanud insuliinisõltuvat suhkurtõbe 
põdejad. Aastail 1993-1994 vastavasta­
tud 29-1 alla 15 aasta vanusel haigel mää­
rati antikehi. 97-1 insuliinisõltuvat suh­
kurtõbe põdejal määrati HLA-DR ja 
HLA-DQ alleele. Teise rühma kuulus 71 
lapseeas alanud insuliinisõltuvat suhkur­
tõbe põdeja tervet õde-venda, keda uuriti 
nii antikehade kui ka HLA regiooni allee­
lide esinemise osas ja jälgiti kolm aastat 
insuliinisõltuva suhkurtõve tekke suhtes. 
Tervete kontrollrühma kuulus 614 las­
teaia- ja koolilast vanuses 3-18 aastat, 
kellel määrati ICA ja GADA, ning 269 ars­
titeaduskonna üliõpilast ja doonorit, keda 
uuriti HLA-DR ja HLA-DQ alleelide suh­
tes.
ICA määrati immunofluorestsentsmee- 
todil (6), GADA kvantitatiivse immuno- 
pretsipitatsiooni radioligandsel meetodil 
(8) ja LA-2A radioimmunoloogilisel meeto­
dil (13). ICA tulemuste võrreldavus teiste 
töödega tagati ICA standardiseerimise re- 
ferents-standardi kasutamisega (7), 
GADA ja IA-2A võrreldavus aga positiiv­
se standardseerumi kasutamisega (10, 
13). HLA-DR ja HLA-DQ alleele määrati 
originaalmeetodil Sjöroosi järgi (simulta- 
neus triple-label hybridization assay for 
HT .A alleles) (12). HLA alleele uuriti ka­
hes etapis. Eismalt uuriti DQB1*0201,
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*0301, *0302, *0602/0603 suhtes. Neil, kel 
esines DQB1*0201, määrati ka DQA1 
*0201 ja *0501. Neil, kel esines 
DQB1*0302, uuriti DRB 1*0401, *0402, 
*0403, *0404, *0405, *0408. DQB1 *0301 
ja *0302 positiivseid indiviide uuriti 
DQB1*0304 suhtes.
Alleelide ja antikehade leviku erinevu­
se hindamiseks kasutati x2- ja Fisheri tes­
ti. Normaalse jaotumusega muutujate 
kiijeldamisel kasutati keskmist ja stan- 
dardhälvet. KorrelatsioonanalUüs tehti 
Spearmani meetodil. Statistiliselt oluli­
seks peeti P<0,05. Iga uuritud alleeli 
jaoks leiti äansside suhe {odds ratio) (SS). 
Vajaduse korral kasutati Haldane’i kor­
rektsiooni. Multiiblite võrdluste korral 
kasutati P väärtuse korrelatsiooni Bon- 
ferroni järgi (3).
Tulemused. Kõige sagedam antikeha 
vastavastatud lapseeas alanud insuliini- 
sõltuvat suhkurtõbe põdejail oli ICA 
(79%-l) (vt. joonis 1.) Järgnesid GADA 
38%-l ja IA-2A 35%-l juhtudest. Vähemalt 
üks mõõdetud antikehadest oli leitav 
86%-l vastavastatud insuliinisõltuvat 
suhkurtõbe põdejaist, kõik kolm uuritud 
antikeha ainult 17%-1 indiviididest.
Üks ja rohkem uuritud antikehadest oli 
leitav 13-1 (18%) insuliinisõltuva suhkur­
tõvega patsientide õel-vennal. Kõige sage­
damini leitavaks antikehaks oli GADA — 
17%-1. Järgnesid ICA (7%) ja IA-2A (6%). 
Enamikul sellest rühmast (82%-l) ei lei­
tud ühtegi antikeha.
Tervete lasteaia- ja koolilaste seas leiti 
ICA-d 10-1 (1,6%) ja GADA-d 14-1 (2,3%). 
Kaks ICA- ja GADA-positiivset isikut hai­
gestus edaspidi insuliinisõltuvasse suh- 
kurtõvesse. Samu antikehi uuriti 1994. 
aastal korduvalt neil kaheksal, kellel 
1991. aastal leiti seerumist ICA ning kes 
polnud haigestunud. Selgus, et pooltel 
neist oli ICA kadunud, GADA tiiter aga 
vähenenud.
Uuritud alleelidest oli Eestis insuliini­
sõltuvat suhkurtõbe põdejail kõige sage­
damini HLA-DQB1*0302 — 66%-l (vt. joo­
nis 2). Järgnes HLA-DQB1*0201 (55%). 
Mõlemad alleelid esinesid neil haigetel 
statistiliselt oluliselt sagedamini kui üld- 
populatsioonis. Meie uuritud HLA-DQB 1 
alleelidest kandis suuremat riski insulii­
nisõltuva suhkurtõve suhtes HLA- 
DQB 1*0302 (SS 8,9), mis ületas HLA- 
DQB 1*0304 poolt edastatava haigestu- 
misriski (SS 7,3). Viimati nimetatud 
alleeli esines haigete hulgas küll harva, 
ainult 5%-l juhtudest. Statistiliselt olulise 
suurenenud insuliinisõltuva suhkurtõve 
riskiga oli seotud HLA-DQB1*0201 (SS 
2,7; P<0,05).
Uuritud HLA-DQB 1 alleelidest mada­
laima insuliinisõltuva suhkurtõve riskiga 
oli Eestis *0602/0603. See alleel oli 44%-l 
Eesti populatsioonist ja ainult 2%-l insu­
liinisõltuvat suhkurtõbe põdejaist. 
DQB1*0602/0603 vähendas haiguse riski 
38 korda võrreldes nendega, kellel seda 
alleeli ei olnud. Samuti oli madala insulii­
nisõltuva suhkurtõve riskiga DQB1*0301 
(SS 0,2; P<0,05).
Neil haigeil kõige sagedamini esinev 
kahe alleeli kombinatsioon oli HLA- 
DQB 1*0201-DQA 1*0501, mida leiti pool­
tel uurituist. Tervete kontrollrühmas oli 
seda kombinatsiooni samuti märkimis­
väärselt — 22%-l. Insuliinisõltuvat suh­
kurtõbe põdejate hulgas oli sageduselt 
järgmine kombinatsioon HLA- 
DQB1*0302-DRB1*0401, mida leiti 43%-l 
uurituist, tervete seas aga ainult 5%-l. 
Nende kahe alleelikombinatsiooniga 
kaasnenud insuliinisõltuva suhkurtõve 
risk oli vastavalt 3,6 ja 13,9.
71 õdede-vendade rühma liikmest hai­
gestus kolmeaastase jälgimise vältel 
kolm. Neist kahel oli HLA-DQB1*0201- 
DQA1*0501 alleelide kombinatsioon, Ees­
ti insuliinisõltuvat suhkurtõbe põdejate 
sagedaim, ja ühel HLA-DQB 1*0302- 
DRB1*0401. Kõik kolm lähisugulast kuu­
lusid nende 13 hulka, kellel leiti antike­
had. Neil kõigil oli leitud vähemalt kahte
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Arutelu. Meie uurimus käsitleb esi­
mest korda insuliinisõltuva suhkurtõvega 
seotud antikehade ICA, GADA ja IA-2A 
levikut Eestis vastavastatud insuliinisõl­
tuva suhkurtõvega laste, nende laste ter­
vete õdede-vendade hulgas ja üldpopulat- 
siooni valimis. Nimetatud antikehade le­
vik Eestis ei erine märkimisväärselt 
teistest populatsioonidest (13). Kõige kõr­
gem kolme antikeha levimus oli ootuspä­
raselt vastavastatud insuliinisõltuva suh­
kurtõvega laste seas, mis kinnitab aktiiv­
selt toimivat autoimmuunset protsessi. 
Antikehade levimusmääralt järgnes õde- 
de-vendade rühm, kelle seas omakorda oli 
antikehade esinemissagedus suurem kui 
tervete populatsioonis. Insuliinisõltuvat 
suhkurtõbe põdejate esimese astme sugu­
laste suurem risk haigestuda kinnitus, 
4% neist haigestus kolme järgneva aasta 
jooksul.
On leitud, et ICA levimus populatsioo­
nides on umbes 10 korda suurem insulii- 
nisõltuva suhkurtõve levimusest, s.t. ena­
mikul ICA suhtes positiivsetel isikutel ei 
arene nimetatud haigus mitte kunagi. 
Üldpopulatsiooni ICA levimuse kõrvuta­
misel meiega sarnaselt tehtud uurimuste­
ga Soomee, Prantsusmaal, Sardiinias ja 
Rootsis selgus, et esineb tugev seos insu­
liinisõltuva suhkurtõve haigestumuse ja 
sama populatsiooni ICA levimuse vahel. 
Neis populatsioonides, kus haigestumus 
oli kõrgem, oli suurem ka ICA levimus- 
määr (r=0,97; P<0,05) (1).
Meie uurimusega täienes teave mitme 
HLA regiooni alleelide leviku kohta Ees­
tis nii üldpopulatsioonis kui insuliinisõl­
tuvat suhkurtõbe põdejate seas. Eesti hai­
gete vastuvõtlikkuse ja kaitsva iseloomu­
ga alleelid ei erine teiste Euroopa 
populatsioonide omast (9, 11). Insuliini­
sõltuva suhkurtõve suhtes riski vähenda­
vateks alleelideks on Eestis DQB1*0301 
ja DQB1*0602^)603, samaselt mitme tei­
se populatsiooniga (9). Märkimisväärne 
on väikese riski alleeli DQB1*0602/0603 
suur levimus Eesti populatsioonis, eriti 
aga tema väga tugev haigestumisriski vä­
hendav toime (neli korda kõrgem kui Soo­
mes). See võib olla üks põhjusi, miks Ees­
tis on haigestumus üle kolme korra väik­
sem kui Soomes. Uuringu käigus leidsime 
senini haruldasena kirjeldatud alleelide 
kombinatsiooni DQB1*0304-DRB1*0408, 
mida esines Eesti üldpopulatsioonis vflga 
harva (0,7%), ent oluliselt sagedamini in- 
suliinisõltuvat suhkurtõbe põdejate rüh­
mas (5%).
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Summary
Immun« and genetic factors of child­
hood onset IDDM in Estonia. Newly dia­
gnosed childhood onset patients with insulin- 
dependent diabetes mellitus (IDDM), their
healthy siblings and background population 
were investigated for the prevalence of IDDM- 
assodated antibodies and HLA region alleles. 
Islet cell (ICA), glutamic acid decarboxylase 
(GADA) and tyrosine phosphatase (IA-2A) 
antibodies and selected HLA-DRB 1, DQA1 
and DQBl alleles were detected. The most 
frequent IDDM associated antibody in newly 
diagnosed childhood onset IDDM patients in 
Estonia is ICA (79%) followed by GADA (38%) 
and IA-2A (35%). Data from several countries 
indicates that the incidence of IDDM is closely 
associated with the frequency of ICA in the 
background population. The most frequent of 
the studied HLA alleles among Estonian 
IDDM patients is HLA-DQB1*0302 (present in 
66%) followed by HLA-DQB1*0201 (55%). The 
single HLA-DQB 1 allele carrying the highest 
risk for IDDM is HLA-DQB1*0302 (OR 8.9) in 
Estonia followed by the novel HLA- 
DQB 1*0304 allele (OR 7.3), although it was 
present only in 5% of IDDM cases. The allele 
carrying the highest protection against IDDM 
in Estonia is HLA-DQB 1*0602/0603. This al­
lele was present in 44% of the Estonian popu­
lation and reduced the risk of IDDM by factor 
of 38 compared to those lacking this allele.
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